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IN PATIENTS WITH END-STAGE HEART FAILURE

DANA L. SCHNEEBERGER

ABSTRACT

Heart failure is a progressive disease in which the heart is no longer able to pump
sufficient amounts of blood to the body. Over six million Americans currently suffer
from heart failure, and although pharmacological and surgical therapies continue to
improve, about 50% of people with heart failure still die within five years of diagnosis.
As the human heart fails, many structural, cellular and molecular alterations occur
that contribute to the decrease in heart function. It has been well-established that some of
these alterations are the result of sympathetic nervous system hyperactivation, and
decreasing sympathetic input with a beta blocker or left ventricular assist device
improves clinical status and also reverses the cellular and molecular alterations associated
with heart failure. We hypothesized that heart failure patients could be trained with
biofeedback and that this method of sympathetic nervous system regulation would also
produce myocardial remodeling in the direction of recovery.
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To test this hypothesis, twenty end-stage heart failure patients listed for heart
transplantation at the Cleveland Clinic received eight sessions of biofeedback-assisted
stress management training.

After biofeedback training, at the time of heart

transplantation, explanted hearts were transported to the laboratory to study the heart
failure phenotype. Data were compared to samples of non-failing, failing (negative
control), and LVAD-supported failing (positive control) hearts.
We found that the inotropic response of left ventricular trabecular muscles to
sympathetic nervous stimulation recovered in patients who received biofeedback training
such that it was not significantly different from the non-failing average. Normalization of
both rate of contraction and relaxation were also shown in the biofeedback group. Beta
adrenergic receptor density was significantly lower in the biofeedback group relative to
non-failing hearts, however significant recovery was shown in some patients. Western
Blot analysis of calcium cycling proteins showed that SERCA and NCX expression in the
biofeedback group was at the same level as the non-failing group, and a significant
decrease in RYR expression was shown in the biofeedback hearts. These data suggest
that biofeedback produces some remodeling of the heart failure phenotype, in the
direction of non-failure.
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CHAPTER I
INTRODUCTION

Cardiovascular disease is the number one killer of men and women in the United
States today, accounting for approximately 55% of all deaths.1

Nearly 83 million

Americans have one or more types of cardiovascular disease, including high blood
pressure, coronary artery disease, angina pectoris, stroke, or congenital cardiovascular
defects.1 Although each form of cardiovascular disease represents a different etiology,
the end-stage of all cardiovascular diseases is heart failure.
Heart failure occurs when the heart is no longer able to adequately pump blood to
the body.

While pharmacological therapies such as beta blockers and angiotensin

converting enzyme inhibitors have been proven to alleviate the symptoms of this disease,
heart failure continues to progress in patients receiving optimal pharmacological
treatment,75 and therefore heart transplantation is still the only option for long-term
success.94 Unfortunately, the number of donor hearts is limited, leveling off at about
2,300 per year,117 and therefore many patients will succumb to the disease before a donor
heart becomes available.

Because of this, it is necessary to explore alternative or

1

adjunctive therapies to ameliorate disease progression or to provide a positive means for
patients to cope with the disease sequelae. This project investigated the efficacy of
biofeedback-assisted stress management training to reverse myocardial remodeling in
patients with end-stage heart failure.

1.1 Normal Cardiac Physiology
Before introducing how the heart remodels during failure, it is important to note
how the heart contracts in a normal, non-diseased state.

Excitation-Contraction Coupling and Calcium Cycling
Excitation-contraction coupling is a series of biochemical processes that converts
electrical signals into mechanical signals through elevation of intracellular calcium.9
Electrical activity is initiated when a specialized bundle of cells in the upper part of the
right atrium of the heart, called the sinoatrial node, initiates a wave of depolarization that
is propagated throughout the myocardium in an organized sequence, ultimately reaching
the atrial and ventricular myocytes. This cardiac action potential depolarizes the myocyte
sarcolemma, allowing calcium to enter the cell through L-type calcium channels. This
small inward flux of calcium triggers a much larger release of calcium from inside the
cell in a process called “calcium-induced calcium release.”

Specifically, the

sarcoendoplasmic reticulum (SR), the main site of calcium storage in the cell, releases
calcium through a calcium-sensitive channel known as the ryanodine receptor (RYR).
This large release of calcium into the cytosol binds to the myofilaments and activates
actin-myosin cross-bridging and cardiac muscle contraction.9,8,49
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Because an increase in intracellular calcium is necessary for cardiac muscle to
contract, there must be a decline in intracellular calcium concentration in order for
cardiac muscle to relax. In cardiomyocyte relaxation, calcium is released from the
myofilaments and is either pumped into the SR or extracted from the cell. Most free
intracellular calcium (about 80%) is taken back up into the SR via the sarcoendoplasmic
reticulum calcium ATP-ase (SERCA). Under baseline conditions, SERCA activity is
partially inhibited by a calcium regulatory protein called phospholamban (PLB). When
increased cardiac contractility is needed (such as during exercise or other sympathetic
activation), PLB is phosphorylated and dissociates from SERCA, removing its inhibition
and allowing SERCA to more rapidly remove calcium from the cytosol. For every
molecule of ATP consumed, SERCA pumps two calcium back into the SR. Once inside
the SR, calcium binds to calsequestrin (CALQ), one of several calcium-binding proteins
that holds calcium in the SR until the next contraction. The other 20% of intracellular
calcium is removed from the cell via the sodium-calcium exchanger (NCX). The NCX is
an antiporter that brings three sodium into the cell for every calcium moved out into the
extracellular space. SERCA and NCX are the two major systems involved in reducing
intracellular calcium during cardiac muscle relaxation. Figure 1 provides and overview
of the calcium cycling process which occurs every time the heart beats.5,6,96

The Beta-Adrenergic Signaling Pathway
One of the major pathways existing in the heart that effects both heart rate and
force of contraction through its effects on calcium cycling in the cardiac myocyte is the
beta-adrenergic signaling pathway. Activation of beta-adrenergic signaling causes an
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Figure 1. Calcium cycling in the cardiac myocyte.
Depolarization of the sarcolemma allows calcium to enter the cell
through L-type calcium channels (1 & 2) which triggers the release of
a large amount of calcium from the sarcoendoplasmic reticulum (SR)
through the ryanodine receptor (RYR) (3) and into the cytosol (4 & 5).
This increase in intracellular calcium binds to the myofilaments (6),
causing cardiac muscle contraction. During relaxation, calcium is
released from the myofilaments (7) and is pumped back into the SR
via the sarcoendoplasmic reticulum calcium ATP-ase (SERCA) (8a)
where it binds to calsequestrin (CALQ) until the next contraction.
Some calcium is also extracted from the cell via that sodium-calcium
exchanger (NCX) (8b). Phospholamban (PLB) regulates SERCA
activity, inhibiting it in the baseline state.
(Figure 1 is modified from DM Bers, 1993.)9
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increase in heart rate (chronotropy) and contractility (inotropy), as well as an increase in
the speed of myocardial relaxation (lusitropy).115
The beta-adrenergic signaling pathway (illustrated in Figure 2) is activated when
an agonist such as endogenous neurohormones epinephrine and norepinephrine, or
isoproterenol (a synthetic analogue of norepinephrine), binds to the beta-adrenergic
receptor on the surface of the cardiac myocyte. This causes activation of the stimulatory
G protein (Gs) which is linked to the enzyme adenylyl cyclase (AC). Activation of AC
then catalyzes the dephosphorylation of adenosine triphosphate (ATP) to form cyclic
adenosine monophosphate (cAMP). Acting as a second messenger, cAMP activates
protein kinase A (PKA), which phosphorylates many intracellular proteins including the
L-type calcium channels, myosin binding protein C (MyBP-C), troponin I (TnI),
phospholamban, and ryanodine receptors.71,115
Phosphorylation of the L-type calcium channels on the sarcolemma causes a
greater influx of calcium into the cell during depolarization. By increasing the amount of
intracellular calcium, more calcium is available to bind the myofilaments, and as a result,
contractility is increased.115,126
Located at the level of the myofilaments, myosin binding protein C regulates the
ATPase activity of the actin/myosin complex. Specifically, MyBP-C reduces ATPase
activity, serving as a “brake” on crossbridge cycling.

Phosphorylation of MyBP-C

releases this brake, increasing the actin/myosin ATPase activity and enhancing cardiac
contractility.33,105,115
Also located at the level of the myofilaments, Troponin I is one of the three
regulatory proteins of the troponin complex. As the inhibitory subunit, phosphorylated
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myocyte.
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Beta-adrenergic signaling pathway in the cardiac

Beta-adrenergic agonists bind to beta receptors on the surface of
cardiac myocytes, initiating an intracellular signaling cascade resulting
in the phosphorylation of L-type calcium channels, phospholamban
(PLB), ryanodine receptors (RYR) as well as myosin binding protein
C and troponin I which are located at the level of the myofilaments.
Activation of this pathway results in an increased concentration of
intracellular calcium, ultimately causing an increase in heart rate and
force of contraction.
(Figure 2 is modified from DM Bers, 1993.)9
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Troponin I decreases myofilament sensitivity to calcium, thereby increasing the rate at
which calcium is released from the myofilaments. This free calcium, now in the cytosol,
can be pumped into the sarcoendoplasmic reticulum (via SERCA) or extracted from the
cell (via NCX), decreasing the amount of intracellular calcium and increasing the rate of
myocardial relaxation.105,115
The rate of myocardial relaxation is also increased through phosphorylation of the
regulatory protein phospholamban (PLB), located on the sarcoendoplasmic reticulum
(SR). At baseline, PLB retards the speed at which the sarcoendoplasmic reticulum
calcium ATP-ase (SERCA) pumps intracellular calcium into the SR. When PLB is
phosphorylated, it releases this inhibition, and SERCA pumps calcium into the SR at a
much faster rate.

This decreases intracellular calcium concentration more quickly,

increasing the rate of myocardial relaxation.

In addition to increasing the rate of

relaxation, phosphorylation of PLB also improves contractility. By allowing SERCA to
pump faster, more calcium is taken up into the SR during relaxation, and therefore more
calcium is stored in the SR for release during the next contraction.105,115
In addition to an increase in SR calcium storage, beta-adrenergic signaling also
results in a greater amount of calcium being released from the SR into the cytosol
through phosphorylation of ryanodine receptors. RYR phosphorylation causes these
calcium release channels to be more sensitive to calcium-induced activation, releasing
more calcium into the cytosol where it can bind to the myofilaments and increase cardiac
contractility.49,77

The Muscarinic Signaling Pathways

7

Another set of pathways that exist in the heart to regulate heart rate and force of
contraction are the muscarinic signaling pathways (Figure 3). Muscarinic signaling
pathways are initiated when an agonist such as acetylcholine activates muscarinic
receptors on the cardiomyocyte cell surface. Depending on which subtype of muscarinic
receptor is activated, one of two different intracellular signaling cascades is initiated.20,31
In total there are five subtypes of muscarinic receptors (named M1 – M5 based on
the order in which they were discovered) that signal through two different pathways. The
even-numbered subtypes of muscarinic receptors (M2 and M4) directly antagonize the
beta-adrenergic signaling pathway by inhibiting adenylyl cyclase through activation of
the inhibitory G protein (Gi). This reduces intracellular cAMP concentration and inhibits
PKA from phosphorylating its target proteins, effectively slowing down heart rate. In the
presence of enhanced contractility (due to increased beta-adrenergic signaling), the
M2/M4 signaling pathway can also cause negative inotropic effects in a phenomenon
called “accentuated antagonism.” 20,31,68,69
Agonist activation of odd-numbered muscarinic receptors (M1, M3 and M5) causes
Gq to activate phospholipase C (PLC).

PLC hydrolyzes phosphatidylinositol 4,5-

bisphosphate (PIP2), forming inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
DAG stimulates protein kinase C (PKC), and IP3 travels to the SR where it is received by
the IP3 receptor, a calcium channel that releases calcium from the SR into the cytosol,
increasing heart rate and force of contraction.20,31

1.2 Heart Failure: A Process of Remodeling
Heart failure is characterized by a process of cardiac remodeling involving
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Figure 3. Muscarinic signaling pathways in the cardiac myocyte.
Muscarinic agonists bind to muscarinic receptors on the surface of
cardiac myocytes, initiating one of two intracellular signaling
cascades. Even-numbered muscarinic receptor subtypes, shown in
red, oppose the beta-adrenergic signaling pathway by inhibiting
adenylyl cyclase (AC), ultimately inhibiting the effects of PKA
phosphorylation and decreasing heart rate. Odd-numbered muscarinic
receptor subtypes, shown in blue, activate phospholipase C (PLC)
which produces inositol 1,4,5-trisphosphate (IP3) and ultimately
causes the opening of a calcium channel in membrane of the
sarcoendoplasmic reticulum (SR). Calcium flows into the cytosol
from the SR, increasing intracellular calcium and myocardial
contractility.
(Figure 3 is modified from DM Bers, 1993.)9
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cellular and molecular changes that manifest clinically as changes in heart size, shape and
function. As the human heart fails, it increases in size and mass due to an increase in
individual cardiac myocyte length. Ventricular chambers dilate producing thinner walls,
and the overall geometry of the heart shifts from an ellipse to a sphere.23,24,43,101 The thin
walls of the failing heart cannot normalize wall stress so contractile function declines.
This decline in myocardial contractility emerges as a decrease in both left ventricular
ejection fraction and cardiac output.16
In addition to the structural and functional alterations associated with the failing
heart, there are also changes at the cellular and molecular level which have come to be
known as the heart failure phenotype. These changes include activation of the immune
system, as evidenced by the increased expression of inflammatory cytokines76,109,112, a
recapitulation of the fetal gene program16, including ventricular expression of atrial
natriuretic factor (ANF) and increased expression of both plasma ANF and B-type
natriuretic peptide (BNP)120, and a change in myosin heavy chain isoforms72,85,88,99.
The heart failure phenotype also includes altered calcium homeostasis due to the
differential regulation of various calcium cycling proteins.

Specifically, SERCA

mRNA4,36,82, protein36,52,83, and activity48,52 decrease, causing lower calcium re-uptake
into the sarcoendoplasmic reticulum (SR) and a much lower calcium-induced calcium
release during the next depolarization. Phospholamban mRNA decreases, although it is
uncertain if this is also true at the protein level.36,83

Sodium-calcium exchanger

mRNA10,35,104, protein10,35,53,54,98, and activity10,53,98 are all upregulated in failing human
hearts, increasing calcium extrusion from the cell. Consistently, no changes have been
found with respect to calsequestrin mRNA27,108 or protein27,53,83 expression in failing

10

heart tissue.
Changes in beta-adrenergic signal transduction are also part of the heart failure
phenotype. In heart failure, total beta-adrenergic receptor density is decreased, and betaadrenergic responsiveness to catecholamines is also reduced.18,19,27,38

As a result,

myocardial contractility increases to a lesser degree following beta-adrenergic
stimulation in failing human hearts as compared to non-failing hearts. In other words, the
failing heart does not have the capacity to work harder when metabolic demands are
placed on the body, such as during exercise18. This is the reason why the six minute walk
test is conducted in heart failure patients as a marker of functional exercise capacity.
With all of these structural, cellular and molecular changes in mind, it is clear that
the heart failure phenotype plays a pivotal role in the decreased contractility that is a
hallmark of human heart failure.

1.3 The Autonomic Nervous System in Heart Failure
Another hallmark of heart failure is dysregulation of the autonomic nervous
system. When the heart fails to pump blood effectively, inadequate tissue perfusion is
sensed by the body, and the primary compensatory mechanism initiated to restore cardiac
function is activation of the sympathetic nervous system (SNS). The SNS releases
norepinephrine (NE) which increases heart rate and enhances contractility via the betaadrenergic signaling pathway. While this is a successful short-term solution, chronic
activation of the SNS is maladaptive and generally leads to pathophysiological processes
such as arrhythmias, plaque rupture and myocardial cell death.30,37,115

Sympathetic

hyperactivity also leads to cardiotoxic levels of norepinephrine in the bloodstream, a
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characteristic which has become a diagnostic of heart failure.17,18,59,62 Many studies have
shown a correlation between circulating levels of norepinephrine and worse prognosis in
patients with heart failure.22,25,40
Overactivation of the SNS alone does not produce the entire autonomic
dysregulation in heart failure. Sympathetic overactivity is accompanied by diminished
parasympathetic nervous system (PNS) control of the heart.13,29,93,96 This hypoactivation
of the PNS can have pro-inflammatory consequences that exacerbate the heart failure
condition57,113, and some studies have even suggested that vagal withdrawal may be as
deleterious as the overactive SNS.13 Many studies have shown that restoring a normal
balance of sympathetic and parasympathetic nervous system activation is associated with
improved cardiovascular health.13,39,69

1.4 The Reversibility of Heart Failure
Until about fifteen years ago, heart failure was believed to be irreversible and
amenable only to palliative care. Recent research, however, in patients who have been
hemodynamically supported with a left ventricular assist device (LVAD), has shown that
some of the cellular and molecular alterations associated with the failing heart can be
reversed.
The LVAD is a mechanical pump that is surgically implanted into the abdomen of
many advanced heart failure patients as a bridge to cardiac transplantation (Figure 4).
With attachments at the apex of the left ventricle and the ascending aorta, the LVAD
performs the function of the left ventricle, pumping blood to the rest of the body so that
the ventricular muscle can rest. The patient’s heart continues to beat, however it no
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Figure 4. The left ventricular assist device.
The left ventricular assist device (LVAD) is a mechanical pump that is
surgically implanted into the abdomen of advanced heart failure
patients as a bridge to transplantation. Through its attachment to the
apex of the left ventricle, blood enters the LVAD, and the LVAD
pumps the blood into the circulation via its attachment to the
ascending aorta.
(Figure 4 is from DJ Goldstein, 1998.)44

13

longer actively pumps blood, and it is therefore said to be unloaded.
Clinical studies of patients supported by an LVAD have shown improvements in
both overall health and heart failure status41,58,67. LVAD support has also been shown to
“reverse remodel” the failing heart by reversing many of the cellular and molecular
alterations that are characteristic of the heart failure phenotype. Some of the alterations
discovered in LVAD-supported heart failure patients include: a restoration of both whole
heart41,67,78,89

and

individual

myocyte

size2,28,67,89,125,

improved

contractile

function5,28,41,55,89, a decrease in circulating cytokines112 and catecholamines41,58,111 as
well as decreased plasma ANF and BNP2,122, a reversal of changes in gene
expression5,14,97, an increase in SERCA expression5,55 as well as improvement in calcium
cycling overall5,28,55, an increase in beta receptor density92 and responsiveness5,28,92, and
an inactivation of some of the signaling pathways leading to the disease34,46. Taken
together, these findings illustrate that heart failure is not irreversible as was once
believed.

1.5 Biofeedback
Biofeedback is a process through which individuals learn self-regulation skills
that allow them to control their physiology for the purpose of improving health or
performance. It involves specialized equipment to monitor one or more physiologic
processes and convert the signals into meaningful visual and auditory cues that are fed
back to the client in real time. Typically, sensors are connected to the client, measuring
modalities such as heart rate, muscle tension and finger temperature, and the information
is immediately displayed on a computer screen.
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These physiologic processes are

normally under control of the autonomic, or involuntary, nervous system. Biofeedback
allows individuals to consciously control these involuntary physiologic processes, and in
a clinical setting, this puts control over one’s health and well-being into the hands of the
patients themselves.81,103
While biofeedback can be used solely as operant conditioning, patients suffering
from stress or a disease with a major stress component often benefit from using
biofeedback in tandem with stress management.66

This is because acute stress is

mediated through the autonomic nervous system, and biofeedback trains patients to
control autonomic activation. Specifically, psychological stress activates the sympathetic
nervous system through what is well known as the “fight or flight” response.
Biofeedback is therefore often used to decrease sympathetic nervous system input so that
the parasympathetic nervous system can become more involved in regulating physiologic
functions.87
When biofeedback is combined with stress management, it requires a trained
biofeedback practitioner who does more than just explaining what the biofeedback
equipment is and how it relates to the patient’s physiology, as is done in the operant
conditioning model.81

Here, the biofeedback practitioner must also provide stress

management techniques and relaxation skills such as guided imagery and progressive
muscle relaxation. It also requires individualized training in which patients are evaluated
for the specific vulnerabilities that lead them to hyperarousal. This is often achieved with
a psychophysiologic assessment in which patients are shown how their body responds to
mental stimuli. Baseline levels of physiologic modalities are measured before a series of
mental stress tests and relaxation exercises. The biofeedback practitioner then guides the
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patient through the thought and behavior patterns that contribute to their physiological
vulnerability.81,103 Once the mind-body connection is made, patients can differentiate
between relaxed physiology and hyperarousal, knowing what each feels like.

The

ultimate goal of biofeedback, therefore, is to teach patients how to self-regulate so that
they can calm their physiology when the biofeedback equipment is not in front of them.

Heart Rate Variability
Heart rate variability (HRV) is a physiologic modality that has come into use
more recently as a measure of autonomic balance and cardiovascular resilience. HRV is
a measure of the beat-to-beat fluctuations in heart rate, which like any other stable system
in the body, must be able to change and adapt in order to maintain homeostasis.66 The
main inputs to the cardiovascular system that use feedback mechanisms to regulate heart
rate are the autonomic nervous system, respiration rate, and the baroreceptors. These
oscillations in the system allow it to respond to stress, disease and injury, much like a
boxer shifts his or her stance in order to respond to the next punch.
The clinical relevance of HRV was first noticed in 1965 when a lack of HRV was
observed prior to fetal distress.56 We now know that decreased HRV is associated with
many diseases and disorders involving autonomic nervous system dysfunction or stress
including cardiovascular disease, depression, anxiety, etc.60,66,116 Since then, the field has
evolved, and in 1996, a task force was formed to determine standards of measurement,
interpretation guidelines, and clinical applications of HRV.110
HRV can be measured in several ways, all beginning with an analysis of R waves
on an electrocardiogram (EKG). While heart rate is calculated as the number of R waves
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per minute, HRV is a measured of the amount of time between successive R waves (the
inter-beat interval). Inter-beat interval (IBI) data are measured in milliseconds (msec)
can be calculated from the heart rate by dividing 60 seconds by the heart rate (in beats per
minute). The resulting value is in seconds, so multiplying this value by one thousand will
give you the IBI value in msec (Figure 5). Because heart rate is typically reported as an
average over time (beats per minute), it can be the same value with equal IBIs or with
variable IBIs.

Several studies have shown that variability in the IBI (heart rate

variability) is a marker of prognosis in cardiovascular disease, namely that greater HRV
is a predictor of greater cardiovascular health. It is believed that patients with end-stage
heart failure have little or no variability in their heart rate.12,61,90

1.6 Summary and Hypothesis
As previously mentioned, (1) heart failure has structural and functional biomarkers that allow disease progression or recovery to be measured, (2) autonomic
nervous system dysfunction is a hallmark of heart failure, with an increase in sympathetic
activity and a withdrawal of parasympathetic control (3) the process of heart failure can
be reversed through LVAD support, and (4) biofeedback is a tool that can be used to
teach patients to alter autonomic input to the cardiovascular system.
We hypothesized that use of biofeedback-assisted stress management
training to downregulate sympathetic nervous system activity and upregulate
parasympathetic

nervous

system

activity,

will

provide

a

non-invasive

psychophysiologic means to reverse myocardial remodeling in patients with endstage heart failure.
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R-R Interval

If heart rate = 72 beats per minute, then IBI = (60 seconds / 72 bpm) x 1000
IBI = 833 milliseconds

Figure 5. Heart rate variability.
Heart rate variability (HRV) is the beat-to-beat fluctuation in heart
rate, also called the inter-beat interval (IBI). It has recently joined
other biofeedback modalities as a direct measure of autonomic balance
and cardiovascular resilience. Greater HRV has been associated with
greater cardiovascular health, and patients with end-stage heart failure
are believed to have no HRV.
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CHAPTER II
METHODS

2.1 Patient Selection
Patients were enrolled in the experimental group (failing + BF) if they had advanced
heart failure (New York Heart Association Class III or Class IV) and were listed for
cardiac transplantation at the Cleveland Clinic. All patients received standard medical
therapy for heart failure, including maximally tolerated doses of angiotensin converting
enzyme inhibitors, angiotensin II receptor blockers, aldosterone antagonists and cardiac
resynchronization therapy / implantable cardioverter defibrillators if indicated by their
heart failure cardiologist. Inpatients were also treated with intravenous inotropic agents.
Patients who were excluded from the failing + BF group include those who had a
mechanical assist device at the time of transplant listing or those who required an assist
device while waiting for transplantation. Patients were also excluded if they did not
speak English and required a translator in order to communicate or if they were unable to
return to the Cleveland Clinic for eight visits. Patients in the non-failing, failing and
failing + LVAD groups were gender-, age-, race-, and (in the failing and failing + LVAD
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groups) heart failure diagnosis-matched with those in the failing + BF group.

2.2 Biofeedback Protocol
All patients enrolled in the failing + BF group received the biofeedback-assisted
stress management training, and each patient served as his or her own control. Patients
were not randomized because it was unknown whether advanced heart failure patients
would even be able to do biofeedback. Inpatients awaiting transplant in the hospital were
studied in their rooms twice per week for 4 weeks. Outpatients awaiting transplant at
home were studied in the Clinical Research Unit at the Cleveland Clinic once per week
for 8 weeks. During training, patients were either seated comfortably in a recliner or
lying supine in their hospital bed.
The biofeedback protocol was conducted by a biofeedback-certified psychologist in
the presence of a biofeedback technician. The role of the technician was to hook the
patient up to the biofeedback equipment at the beginning of each session and to monitor
the raw data throughout each session, addressing any noise in the signal, if possible.
Signal artifact as well as anything unusual that may have occurred during the session was
noted by the technician. The technician was also present to confirm that the biofeedback
therapist was using only biofeedback and stress management techniques with the patients.
Specifically, it was important to have an independent party confirm that no
psychotherapy was being conducted during the biofeedback sessions.

Sensors and Screens
Standard biofeedback equipment from Thought Technology (Montreal, QC) was used
to monitor physiologic processes. Physiologic modalities measured included respiration
20

rate, digital peripheral temperature, skin conductance, heart rate, and heart rate variability
in the time domain. Figure 6 shows the four sensors that were used to monitor patients’
physiology, and a summary of values when a person is relaxed is provided in Table I.
To measure respiration rate, patients were asked to exhale fully, and a strain gauge
was placed around their waist, just above the belly button with a small amount of tension.
The strain gauge is sensitive to stretch, and it converts the expansion and contraction of
the patient’s abdomen into a rise and fall in the signal transmitted to the computer. The
software calculates respiration rate from this raw waveform (in breaths per minute).
Digital peripheral temperature was measured using a thermistor that was taped along
the palmar side of the patient’s fifth digit using Millipore medical tape. Changes in
finger temperature were converted into an electrical current which was transmitted to the
computer to display changes in the signal (in degrees Fahrenheit - °F).
To measure the skin’s ability to conduct electricity, or skin conductance, silver-silver
chloride electrodes embedded into Velcro straps were placed onto the pads of the
patient’s second and fourth digits. When in use, a small electrical voltage was applied
through the electrodes, establishing an electrical current in which the patient serves as a
resistor, and the real-time variation in conductance (the inverse of resistance) was
recorded (in microsiemens - µS).
Lastly, heart rate was measured using a blood volume pulse sensor that was taped to
the pad of the patient’s third digit. This sensor uses photoplethysmography to shine
infrared light through the skin and measure the light that is reflected back to the sensor.
Because blood reflects red light and absorbs other colors, the amount of light reflected
back to the sensor changes with the amount of blood flowing through the finger. The
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A

B

C

D

Figure 6. Biofeedback sensors.
Strain gauge (A) used to measure respiration rate; Thermistor (B) used
to measure finger temperature; Electrodes (C) used to measure skin
conductance; Blood volume pulse sensor (D) used to measure heart
rate / heart rate variability.
Photos taken from www.thoughttechnology.com/sensors.htm
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Table I. Physiologic Signals When A Person Is Relaxed
RESP

DPT

SC

HR

6 breaths per minute

~ 90°F

2µS

~ 60-80 beats per minute

RESP = Respiration Rate, DPT = Digital Peripheral Temperature, SC = Skin Conductance, HR = Heart Rate
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blood volume pulse signal is a relative measure from which heart rate (beats per minute)
and inter-beat interval (milliseconds) are calculated. The raw inter-beat interval data
were used to calculate measures of heart rate variability in the time domain.
Custom biofeedback screens were created to provide optimal audio and visual
feedback to the patients in this study. As shown in Figures 7-10, each patient screen
focused on a single physiologic modality.

Figure 11 illustrates a screen that was

customized for the biofeedback therapist and the biofeedback technician to see a realtime summary of all physiologic modalities at the same time.

Session Outline
The first and last study visits (visits 1 and 8) consisted of a custom-designed 32minute psychophysiologic assessment of stress reactivity.

During this assessment

patients were guided through three mental stress tasks, separated by five minute periods
of rest / self-relaxation.

A five-minute self-relaxation was also conducted at the

beginning of each assessment, prior to the stressors. Mental stress tasks included the
Stroop Color Word Test74, Serial Sevens Test102 and a Stressful Event Recall Task103 in
which patients were asked to talk about how it feels to be waiting for a heart transplant.
The six biofeedback-assisted stress management training sessions (visits 2-7) were
each 45 minutes in length and involved basic relaxation training with biofeedback,
predominantly respiration and temperature feedback. Although each training session
began and ended with a 5-minute self-relaxation, the rest of the session consisted of
individualized stress management exercises to which the patient best responded.
A schematic outline of all eight biofeedback sessions can be found in Figure 12.
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Figure 7. Respiration rate patient training screen.
The target breathing rate for patients was 6 breaths per minute. Using
an adaptive pacer ball, patients were paced to breathe at a rate two
breaths per minute less than their current respiratory rate, which was
displayed digitally on the screen (in yellow). A filled line graph of
respiratory amplitude was also displayed for patients to learn to
breathe smoothly and deeply.
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Figure 8. Digital peripheral temperature patient training screen.
In addition to a digital display of finger temperature (in yellow), this
screen also includes a bar graph that is red as temperature rises and
turns blue as temperature falls. The lightbulb is connected to the bar
graph such that a rise in temperature lights up the bulb, and the bulb
gets dimmer as finger temperature drops.
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Figure 9. Skin conductance patient training screen.
This screen shows a slideshow of relaxing images that cycle as the
patient lowers their skin conductance. If skin conductance rises, the
current photo goes out of focus, and the slideshow does not advance.
A digital display of skin conductance is also present on the screen (in
yellow).
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Figure 10. Heart rate variability patient training screen.
Patients were not formally trained using this HRV screen, but HRV
was monitored throughout all sessions. This screen shows an adaptive
pacer ball as well as a line graph displaying the overlap between heart
rate and respiration rate. Bar graphs of HRV in the frequency domain
are also displayed, however this screen was only ever casually referred
to if the green bar was high so that the biofeedback therapist could
provide positive reinforcement to the patient.
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Figure 11. Biofeedback therapist / technician screen.
This screen was created so that all physiologic modalities being
measured could be viewed simultaneously by the biofeedback
technician and the biofeedback therapist.
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Session 1
Psychophysiologic Assessment
5-minute Acclimation
5-minute Self-Relaxation
1-minute Stroop Color Word Test
5-minute Rest (#1)
1-minute Serial Sevens Test
5-minute Rest (#2)
5-minute Stressful Event Recall
5-minute Rest (#3)

Sessions 2 - 7
Biofeedback Training
5-minute Self-Relaxation
35 minutes – Individualized Stress
Management / Biofeedback
5-minute Self-Relaxation

Session 8
Psychophysiologic Assessment
5-minute Acclimation
5-minute Self-Relaxation
1-minute Stroop Color Word Test
5-minute Rest (#1)
1-minute Serial Sevens Test
5-minute Rest (#2)
5-minute Stressful Event Recall
5-minute Rest (#3)

Figure 12. Schematic Outline of Biofeedback Sessions.
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Homework
All patients were provided with relaxation CDs, handheld thermometers and daily
record sheets. Patients were asked to practice at least 20 minutes per day on their own in
between sessions, recording their daily stress levels and their finger temperature before
and after relaxation practice. This home practice encouraged optimal learning of the
biofeedback skills which were being taught in the training sessions. Daily record sheets
(Figure 13) were collected at each visit, and patients were asked about the frequency and
success of practice, which were also recorded.

Quality of Life Assessment
In order to assess whether biofeedback-assisted stress management enhanced
quality of life for patients awaiting heart transplantation, two questionnaires were
administered prior to the psychophysiologic assessment in the first and last biofeedback
sessions. These included the RAND Short-Form 36 (SF-36) general health survey79,80,119
and the heart failure-specific Kansas City Cardiomyopathy Questionnaire (KCCM)47.
Both were scored according to standard metrics.47,118

Subjective Data
Patients were also asked several times throughout each biofeedback session to selfreport aloud their heart failure status, level of relaxation and mood, and these responses
were recorded. A 5-point Likert scale was used for each question with 1 being the most
negative response and 5 being the most positive.
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Figure 13. Daily record sheet.
Copies of this data sheet were provided to all patients, and they were
encouraged to practice relaxation skills at home in between sessions,
fill out these data sheets (one/day), and return them at their next visit.
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Clinical Assessment
Clinical course was assessed in ambulatory outpatients during the first and last
biofeedback sessions. Upon arrival, patients were asked to lay supine for 30 minutes
before blood was drawn for measurement of plasma norepinephrine. Following the
psychophysiologic assessment in these two sessions, a six minute walk test was
performed for the objective evaluation of functional exercise capacity.3

2.3 Human Heart Tissue Procurement
Human heart tissue was acquired at the time of cardiac transplantation. Immediately
after excision, each heart was obtained from the operating room and placed into chilled
cardioplegia (concentration in mM: 77.0 NaCl, 20.0 KCl, 10.0 NaHCO3, 14.0 Glucose,
0.1 CaCl2) for transport to the laboratory. Non-failing human hearts were obtained
through LifeBanc of Northeast Ohio from unmatched organ donors in which the heart
was not suitable for transplantation due to histoincompatibility or a difference in organ
size. Failing human hearts, including those who received biofeedback training and those
supported by an LVAD, were obtained from recipients undergoing heart transplantation
at the Cleveland Clinic. Informed consent was acquired prior to tissue procurement in
accordance with an approved IRB protocol (IRB #2378, C Moravec Principal
Investigator).

2.4 Cardiac Muscle Function
All muscle function experiments were performed at the time of transplant. Explanted
hearts were brought back to the lab, and fresh left ventricular trabecular muscles were
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immediately dissected from the endocardial surface of the heart. Individual muscles were
placed between two O-rings and hung in a tissue bath filled with Krebs-Henseleit buffer
(composition in nM: 100 NaCl, 4 potassium chloride (KCL), 1.5 magnesium sulfate
heptahydrate (MgSO4*7H2O), 20 sodium bicarbonate (NaHCO3), 1.5 sodium phosphate
(NaH2PO4), 20 sodium acetate, 10 glucose, 0.1 ascorbic acid, 2.5 anhydrous calcium
chloride, 5 I.U. insulin) maintained at 37°C (Figure 14).
For the next hour, total muscle tension was monitored and adjusted every 15 minutes
to ensure that it stayed close to 1.0g. No stimulus was given during this time. After the
muscles stabilized, GRASS stimulators were turned on to provide repeat stimulation
(10V, 1Hz), and the minimum voltage necessary to elicit muscle contraction (called the
threshold voltage) was determined. To determine the threshold voltage, voltage was
dialed back to 1V and steadily increased by 1 until the muscle began to contract. Voltage
was then reduced by 1V (a voltage where the muscle did not contract) and slowly
increased by 0.2V until the muscle contracted repeatedly (for ~ 30 seconds).
The stimulator for each muscle was set to a voltage 20% greater than the empirically
determined threshold voltage, and this voltage was used for the remainder of the
experiment. A length-tension curve was then performed to determine the length at which
each muscle produces its greatest contraction (Lmax). With each muscle at its Lmax, the
effect of any experimental manipulation can be compared across muscles. To find Lmax,
baseline resting tension (RT) and developed tension (DT) were recorded, and after 1
minute, each muscle was stretched by 0.1mm. RT and DT were recorded 1 minute later,
and the process continued (stretch muscles, wait 1 minute, record RT and DT) until there
was a large increase in RT and DT no longer or barely increased. After Lmax was
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Human
Left Ventricular
Trabecular Muscle

Tissue bath with
Krebs-Henseleit Buffer
maintained at 37°C
Figure 14. Muscle bath set-up.
Human left ventricular trabecular muscles are dissected from the
endocardial surface of the heart and secured between two O-rings.
Muscles are then hung in an oxygenated tissue bath containing KrebsHenseleit buffer which is maintained at 37ºC.
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reached, muscles stabilized in the tissue baths for 30 minutes, and only muscles with
developed tension greater than 0.20g were used for the experiment.
Baseline data were collected for 5 minutes before 1µM isoproterenol (ISO), a
laboratory analogue of norepinephrine, was added directly to each tissue bath to mimic
stimulation by the sympathetic nervous system. After 10 minutes of data collection under
the influence of ISO, data were saved in the data acquisition software (LabChart 7 Pro),
and the tissue baths were lowered. Calipers were used to measure the length of each
muscle between the O-rings, and then each muscle was carefully cut out as close to the
O-rings as possible. Muscles were dried in bibulous paper for exactly 15 minutes and
immediately weighed. The cross-sectional area (XSA; in mg/mm) of each muscle was
calculated by dividing the weight of each muscle by its length.
Muscle function at baseline (Lmax) as well as the response to isoproterenol was
analyzed for six contractile parameters including RT, DT, time to peak tension (TPT),
time to half relaxation (THR), peak rate of tension rise (+dT/dt), and peak rate of tension
fall (-dT/dt) (Figure 15).

2.5 Sarcolemmal Membrane Isolation and Purification
In preparation for beta-adrenergic and muscarinic receptor density measurements,
sarcolemmal membrane fragments were isolated and purified from frozen human heart
tissue which had been stored at -80°C. Frozen tissue samples weighing 2.0g ± 0.2g were
each placed into 20mL of chilled homogenization buffer A (composition: 10mM N-(2Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES), 5mM ethylene glycolbis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), 12.5mM magnesium
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THR
DT

Tension (g)
Time (sec)

RT
TPT

+dT/dt
Rate (g/sec)
Time (sec)

-dT/dt

Figure 15. Individual muscle contraction showing six contractile
parameters.
Muscle function was evaluated with respect to six contractile
parameters. Resting tension (RT) is the tension produced by the
muscle at rest. Developed tension (DT) is the force produced by the
muscle during contraction. Time to peak tension (TPT) is the time it
takes for the muscle to reach the peak of its contraction. Time to half
relaxation (THR) is the time it takes for the muscle to get from that
point of peak contraction to halfway through its relaxation. Peak rate
of tension rise (+dT/dt) is the maximal rate of contraction (represented
by the steepest point of the line leading to the peak of the muscle
contraction). Peak rate of tension fall (-dT/dt) is the maximal rate of
relaxation and is represented by the steepest point of the relaxation
line moving back toward RT.
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chloride (MgCl2), 250mM sucrose, 20µg/mL leupeptin, 20µg/mL phenylmethylsulfonyl
fluoride (PMSF), 20µg/mL bacitracin, 20µg/mL benzamidine) and homogenized using a
Polytron homogenizer until there was little foam and no visible chunks of tissue floating
in the homogenate. In order to minimize heat production and thereby the potential
destruction of proteins, homogenization was carried out on ice in 3-second bursts with 5
seconds of rest in between activity to allow the homogenization probe to cool.
Homogenates were centrifuged at 4°C and 300 x g for 5 minutes so that heavier
organelles such as nuclei and mitochondria precipitated out. Avoiding the pellet and
layer of fat, supernatants were recovered and incubated in 0.5M KCl at 4°C for 15
minutes to remove myofilaments. These suspensions were centrifuged at 4°C and 40,000
x g for 15 minutes in order to pellet the membrane fraction. Supernatants were discarded,
and pellets were added to chilled homogenization buffer B (composition: 20mM HEPES,
5mM EGTA, 12.5mM MgCl2, 100mM sodium chloride (NaCl), 10µg/mL leupeptin,
20µg/mL PMSF, 20µg/mL bacitracin, 20µg/mL benzamidine).
Pellets were dounce homogenized in buffer B on ice, 10 times with a loose-fitting
pestle and 10 times with a tight-fitting pestle, in order to purify the membrane fraction.
Preparations were centrifuged at 4°C and 40,000 x g for 15 minutes, and pellets were
recovered and dounce homogenized a second time (in buffer B, on ice, 10 times with a
loose-fitting pestle and 10 times with a tight-fitting pestle) before a final centrifugation to
refine the membrane preparation (again at 4°C and 40,000 x g for 15 minutes). Pellets
were resuspended in buffer B + 10% glycerol (preserves the membrane preparations
throughout storage) and completely solubilized using a motorized dounce homogenizer.
Aliquots were stored at -80°C.
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2.6 Measurement of Total Protein for Receptor Density Analysis
Total protein concentration was determined by the Lowry method using Bio-Rad
reagents. Standards containing known concentrations (0, 500, 1000, 2000, 3000 and
4000 µg/mL) of bovine serum albumin (BSA) were pipetted into a 96-well microtiter
plate in triplicate. Membrane preparations were diluted 1:2 in deionized water (dH2O)
and also added to the microtiter plate in triplicate. Reagent A, an alkaline copper tartrate
solution, was added to each standard and sample to bind to the peptide bonds in all
proteins. A dilute folin reagent, Reagent B was then added to each standard and sample
to recognize Reagent A and to produce a characteristic blue color directly proportional to
the amount of protein in the sample. After a 15-minute incubation at room temperature,
absorbance was read at 750nm.

Using the absorbance values for the known

concentrations of BSA to generate a standard curve, the total protein concentration for
each unknown sample was determined by interpolation.

2.7 Total Beta-Adrenergic Receptor Density
Beta-adrenergic receptor density was measured by radioligand binding analysis. In
order to optimize conditions for radioligand binding, membrane titer assays were run.
Specifically, six polypropylene tubes were arranged on ice for each membrane fraction to
be measured. The assays were run in triplicate with three tubes used to measure total
binding and three tubes to measure non-specific binding. A reaction buffer (HEM)
(composition in mM: 20 4-(2-hydroxyethyl)-1-piperaineethanesulfonic acid (HEPES), 15
EGTA, 1.25 MgCl2) plus 0.1% BSA was added to all six tubes for each sample.
Propranolol (10-5M), an unlabeled non-selective beta-adrenergic receptor blocker, was
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then added to each non-specific binding tube.
antagonist,

125

Next, a non-selective radiolabeled

I-Cyanopindolol (ICYP) (30pM), was added to all reaction tubes. Finally,

each membrane fraction was prepared in HEM + BSA buffer to a final protein
concentration of 25µg/µL and added to all reaction tubes. All tubes were mixed and
incubated in a shaking water bath at 37°C and 65 RPM for one hour.

Following

incubation, contents of each reaction tube were trapped onto glass fiber filter paper using
a cell harvester. Forceps were used to carve out an individual filter for each reaction
tube, and each filter was placed into a new polypropylene tube. The new polypropylene
tubes were taken to a gamma radiation counter where the amount of radioactivity trapped
on each piece of filter paper was determined. Each tube was read for one minute, and 125I
was measured in counts per minute. Triplicate values were averaged, and average nonspecific binding was subtracted from average total binding to obtain a specific binding
value for each sample.

Because our laboratory has previously determined that the

optimal running condition for radioligand binding assays is at 10% of the dissociation
constant (Kd)92, the amount of membrane necessary to run under this condition was
calculated for each sample.
Next the radioligand binding assay was performed using seven doses of ICYP in the
presence of 10-5M propranolol. Similar to the membrane titer assay, everything was run
in triplicate, with three tubes for measuring total binding and three tubes for measuring
non-specific binding for each dose of ICYP for each sample (42 tubes / sample). The
experiment was run with all tubes on ice. The highest concentration of ICYP (250pM)
was prepared in HEM + BSA buffer, and subsequent doses were achieved via serial
dilution (in pM: 125, 63, 31, 16, 8, 4). HEM + BSA buffer and propranolol were added
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as described in the membrane titer assay. Each ICYP dose was added to six tubes (three
total binding and three non-specific binding) for each sample, from the lowest
concentration to the highest. Membrane preparations were prepared in HEM + BSA
buffer according to the calculations from the membrane titer assay (at 10% Kd) and added
to all 42 tubes for each sample.

All tubes were mixed, incubated, harvested, and

radioactivity was quantified again using the same procedure as in the membrane titer
assay. In order to determine total density and Kd for each sample, Scatchard analyses
were performed. Figure 16 shows a typical saturation curve and Lineweaver-Burk plot
generated in the Scatchard analysis.

2.8 Total Muscarinic Receptor Density
Much like the measurement of beta-adrenergic receptor density, total muscarinic
receptor density was measured by radioligand binding assay, preceded by membrane titer
analysis in order to optimize conditions. The membrane titer assay protocol was the
same as that outlined in section 2.8, except that 1µM atropine was used as the unlabeled
non-selective muscarinic receptor blocker, and 250pM 3H-Quinuclidinyl benzilate (QNB)
served as the non-selective radiolabeled antagonist. Also, following the cell harvesting
step, individually carved filters were placed into scintillation vials and incubated in a
hybridization oven at 42°C until dry (~5 minutes). All scintillation vials were then filled
with Cytoscint scintillation fluid, mixed and wiped with a dryer sheet to prevent
artificially high radiation readings from static. Before vials were read, they sat overnight
on the benchtop at room temperature.

The next day, all vials were taken to the

scintillation counter where each vial was read for 2 minutes. Once again 3H was
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Figure 16. Typical saturation curve and Lineweaver-Burke plot.
Scatchard analyses generate a saturation curve and a Lineweaver-Burk
plot. The saturation curve (top) illustrates the relationship between the
concentration of radioactivity used and the amount of binding. The
Lineweaver-Burk plot (bottom) illustrates the relationship between the
amount of specific binding and the ratio of bound to free radioactivity.
The x-intercept represents the density (Bmax) of the measured
receptor, and the slope represents the binding affinity (Kd).
(Abbreviations: B = specific binding, B / F = the ratio of bound to
free radioligand)
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measured in counts per minute, and specific binding values were obtained by subtracting
average non-specific binding from average total binding. This protocol was recently
worked out in our laboratory, and it was determined that the optimal running condition
for radioligand binding assays aimed at measuring muscarinic receptors is at 10% of the
Kd (unpublished). The amount of membrane necessary to run under this condition was
calculated for each sample.
To measure total muscarinic receptor density via radioligand binding, the same
general process described in section 2.8 was employed. In this case, eight doses of 3HQNB were used in the presence of 1µM atropine.

The highest dose of QNB was

1500pM, and non-logarithmic serial dilutions were used to prepare the remaining seven
doses (in pM: 900, 540, 270, 135, 68, 27, 11). The cell harvesting steps were the same as
those described above, and again, Scatchard analyses were performed to obtain final total
binding and Kd values for each sample.

2.9 Tissue Homogenization for Western Blotting
Homogenization was done on ice in a Tris-EDTA (ethylenediaminetetraacetic acid)
radioimmunoprecipitation assay (RIPA) buffer (composition: 20mM Tris, pH 7.4;
100mM NaCl; 5mM EDTA, pH 8.0; 10% glycerol; 50mM sodium fluoride (NaF); 1%
Triton X-100; 0.1% sodium dodecyl sulfate (SDS); 1% sodium deoxycholate (DOC);
1mM sodium pyrophosphate (Na4P2O7); 1mM sodium orthovanadate (Na3VO4);
10µg/mL PMSF) which also contained a standard cocktail of protease inhibitors for
mammalian tissues (Sigma). All protease / phosphatase inhibitors were added just before
use. Homogenization of human heart tissue samples (~ 300mg each) was performed on
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ice using a Polytron homogenizer 3 times for 3 seconds each with 5-second rests between
each homogenization. Homogenates were centrifuged at 4°C and 2,000 RPM for 10
minutes. Supernatants were recovered, and aliquots were stored at -80°C.

2.10 Measurement of Total Protein for Western Blotting
Total protein concentration was determined by the Lowry method using the Bio-Rad
DC (detergent-compatible) protein assay kit. The process was the same as the protein
assay used prior to receptor density measurements, except for the following: standard
concentrations were 0, 200, 400, 600, 800 and 1,000 µg/mL BSA; homogenates were
diluted 1:50; and Reagent S, a surfactant solution was added to Reagent A before it was
added to the microtiter plate.

2.11 Western Blotting to Measure Calcium-Cycling Proteins
Homogenates were diluted in Laemmli buffer containing β-2-mercaptoethanol to a
concentration of 4µg/µL. Proteins were separated on 8.0% (SERCA) or 7.0% (CALQ)
SDS-PAGE running gels with 4% stacking gels. In the case of RYR, a 4-20% precast
linear gradient gel (Bio-Rad) was used for protein separation. Gels were run at 125V in
chilled running buffer (composition in mM: 19 tris(hydroxymethyl)aminomethane (Tris),
3.5 SDS, 192 glycine) until the dye front reached the bottom of gel (~90 minutes).
Because RYR is such a large, globular protein, it was run at 125V for 2.5 hours on ice to
avoid overheating.
Proteins were electroblotted onto polyvinylidene fluoride (PVDF) membranes in icecold transfer buffer (composition in mM: 17 Tris, 181glycine, 20% methanol (MeOH))
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on ice at 100V for 2 hours (3 hours for RYR gels). Blots were blocked with 5% milk in
tris buffered saline (TBS)-Tween for 2 hours and incubated in primary antibody at 4°C
overnight on a rotisserie. The next day, blots were washed with TBS-Tween 4 times for
5 minutes each and incubated (shaking) in secondary antibody at room temperature for 1
hour. Exact antibody conditions can be found in Table II.
Blots were washed again with TBS-Tween 4 times for 5 minutes each. Blots were
then developed via chemifluorescence using the Odyssey infrared scanner (Li-Cor, NE)
and quantified with Odyssey version 3.0 software. Each sample was normalized to a
non-failing sample that was run on every gel, which allowed for comparisons across gels.

2.12 Data Analysis
Biofeedback, Quality of Life and Clinical Data
For all before and after biofeedback training analyses, paired t-tests were
performed. If the data were not normally distributed, then a Wilcoxon matched-pairs
signed rank test was used to make comparisons.
Across-session analyses were performed using a one-way repeated measures
analysis of variance (ANOVA) with Newman-Keuls post-hoc testing when necessary.
Freidman tests with Dunn’s Multiple Comparison post-hoc tests were performed when
the data did not follow a normal distribution.
Inpatient versus outpatient comparisons were made using a 2-way repeated
measures ANOVA and Bonferroni post-hoc analyses.
In all cases, alpha was set at 0.05, and analyses were performed using GraphPad
Prism software, version 5.02 (San Diego, CA).
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Table II. Western Blot Antibody Conditions
Host

Primary Antibody

1° Ab Dilution

2° Ab Dilution

Mouse

Anti-SERCA

1:30K

1:20K

Rabbit

Anti-NCX

1:10K

1:10K

Mouse

Anti-RYR

1:3K

1:10K

Rabbit

Anti-CALQ

1:10K

1:20K

SERCA, RYR and CALQ primary antibodies were from Thermo Scientific (Golden, CO). NCX
primary antibody was from Swant (Switzerland). All secondary antibodies were from Li-Cor
Biosciences (Lincoln, NE).
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Removing Artifact from Heart Rate Variability Data
Before comparisons were made with respect to heart rate variability, the raw data
had to be analyzed for potential artifacts. Artifacts were defined as inter-beat intervals
that did not match up with a pulse on the blood volume pulse trace. Raw inter-beat
interval data were scrolled through, and the cursor on the blood volume pulse trace
“jumped” from pulse to pulse. When the cursor did not land on a pulse, then this was
considered to be an artifact, and it was manually removed using one of three strategies:
(1) if the IBI value was longer than those nearby, then it was split into two equal IBI
values, (2) if the IBI value was longer than those nearby and the consecutive IBI was
shorter than those nearby (or vice versa; if the two consecutive IBIs were a relatively
short value followed by a relatively long value), then the two consecutive IBIs were
averaged, and (3) if there were two consecutive short IBI values, then the IBIs were
added. All heart rate variability artifact removal was performed using CardioPro Infiniti:
HRV Analysis Module for BioGraph Infiniti software (Thought Technology, Montreal,
QC).

Biological Data
A one-way ANOVA was used to compare non-failing, failing, failing + LVAD and
failing + BF groups with respect to muscle function, total receptor density and Kd (betaadrenergic and muscarinic), as well as the relative presence of calcium-cycling proteins.
When necessary, Newman-Keuls post-hoc tests were performed. If any one of the groups
did not follow a normal distribution, as determined by the Kolmogorov-Smirnov test,
then a Kruskal-Wallis test was performed with Dunn’s Multiple Comparison post-hoc
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analysis. Alpha was set at 0.05, and analyses were performed using GraphPad Prism
software, version 5.02 (San Diego, CA).

Correlation Data
To determine whether success with biofeedback was related to biological change,
linear regressions were performed. The correlations were analyzed using GraphPad
Prism software, version 5.02 (San Diego, CA), and alpha was again set at 0.05.
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CHAPTER III
RESULTS

3.1 Biofeedback Data
Table III shows demographic data on the 35 patients enrolled in the biofeedback
portion of this study. Highlighted in gray are the 20 patients who completed the entire
biofeedback-assisted stress management training protocol (all eight sessions of
biofeedback), and only these 20 patients were used in the biofeedback data analysis.
Summary demographics on these 20 patients can be found in Table IV.

Respiration Rate
The first physiologic modality focused on during biofeedback-assisted stress
management training was respiration. Figure 17 shows that patients were able to lower
their average respiration rate from 14.9 ± 2.9 breaths per minute in session 1 (before
biofeedback training) to 9.4 ± 2.7 breaths per minute in session 8 (after biofeedback
training) (p < 0.001). In order to determine how many training sessions it took before a
significant change occurred, average respiration rate was also evaluated across sessions.
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Table III. Demographics of the 35 End-Stage Heart Failure Patients Enrolled in the Study

IP 1
IP 2
IP 3
IP 4
IP 5
IP 6
IP 7
IP 8
IP 9
IP 10
IP 11
IP 12
IP 13
IP 14
IP 15
IP 16
IP 17
IP 18
IP 19
IP 20
IP 21
OP 1
OP 2
OP 3
OP 4
OP 5
OP 6
OP 7
OP 8
OP 9
OP 10
OP 11
OP 12
OP 13
OP 14

Age
59
66
61
53
61
58
27
46
52
45
65
63
28
69
61
68
50
61
55
66
58
59
20
60
52
67
43
44
61
49
20
46
64
66
61

Sex
M
M
M
F
F
M
M
M
F
M
M
F
F
M
M
M
M
M
F
M
M
M
M
F
M
F
M
M
M
M
M
F
M
M
M

Race
W
W
W
B
W
W
W
W
W
W
W
W
B
W
B
W
B
W
W
W
W
W
H
W
W
B
B
W
W
W
W
B
W
W
W

Diagnosis
ICM
ICM
ICM
DCM
DCM
DCM
CONG
Restrictive CM
DCM
CONG
DCM
ICM
DCM
ICM
DCM
ICM
DCM
Amyloidosis
HCM
DCM
DCM
DCM
DCM
DCM
DCM
DCM
ICM
CONG
ICM
ICM
Restrictive CM
DCM
DCM
DCM
ICM

LVEF (%)
15
10
20
15
10
30
10
60
15
55
15
20
20
15
10
51
20
20
10
30
37
20
18
25
15
10
12
15
20
20
30
10
30
10
19

Medications
ACE I, BB
AAR, BB, DIG
ACE I, BB, DIG
ACE I, BB
ACE I, BB, DIG
ACE I, BB
N/A
N/A
AAR, ACE I, BB, DIG
BB, DIG
ARB, BB, DIG
ACE I, BB, DIG
INO
AAR, ACE I, BB, DIG, INO
BB, INO
AAR, BB, DIG, INO
AAR, BB, DIG
N/A
AAR, BB
ACE I, BB
AAR, BB
ACE I, BB, DIG
ACE I, BB, DIG
Not Listed for Transplant
ACE I, BB
AAR, ACE I, BB, DIG, OVD
ACE I, BB
ACE I, BB, DIG
ACE I, DIG
BB
ACE I, BB
BB
ACE I, BB, DIG
AAR, ACE I, BB
BB, OVD

IP = inpatient; OP = outpatient; M = male; F = female; W = white; B = black; H = Hispanic; DCM = dilated
cardiomyopathy; ICM = ischemic cardiomyopathy; HCM = hypertrophic cardiomyopathy; CONG = congenital; AAR =
anti-arrhythmic; ACE I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BB = beta
blocker; DIG = digoxin; INO = inotrope; OVD = other vasodilator
= patients who completed all 8 sessions of biofeedback

50

Table IV. Demographics of the 20 End-Stage Heart Failure Patients
Who Completed All 8 Sessions of Biofeedback

Patient Status (n = 20)
Inpatient
Outpatient

12 (60%)
8 (40%)
56 ± 10

Age, y
Gender
Male
Female

17 (85%)
3 (15%)

Race
White
Black

16 (80%)
4 (20%)

NYHA
III
IV

17 (85%)
3 (15%)

Diagnosis
DCM
ICM
CONG
Restrictive CM
Amyloidosis

9 (45%)
6 (30%)
3 (15%)
1 (5%)
1 (5%)

LVEF, %

23 ± 15

Medications
AAR
ACE I
ARB
BB
DIG
INO

4 (20%)
9 (45%)
1 (5%)
15 (75%)
10 (50%)
3 (15%)

DCM = dilated cardiomyopathy; ICM = ischemic cardiomyopathy; CONG = congenital; AAR
= anti-arrhythmic; ACE I = angiotensin converting enzyme inhibitor; ARB = angiotensin
receptor blocker; BB = beta blocker; DIG = digoxin; INO = inotrope
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Figure 17. Average respiration rate during self-relaxation before
and after biofeedback training.
Patients lowered their respiration rate from 14.9 ± 2.9 breaths per
minute before biofeedback training to 9.4 ± 2.7 breaths per minute
after biofeedback training (p < 0.001).
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After only three sessions of biofeedback training (session 4), patients were breathing at a
significantly lower rate than they were in session 1 before they had any formal training (p
< 0.05), and respiratory rate continued to decrease throughout the remaining sessions
(Figure 18).
Respiration rate was also evaluated as the percentage of time patients spent
meeting specific criteria before and after biofeedback training. Self-relaxation portions
of the psychophysiologic assessment, including the 5-minute self-relaxation at the
beginning of the session and the rest periods (each five minutes in length) following each
mental stress task, were aggregated and labeled as “relaxation time.” As shown in
Figure 19, patients spent a significantly greater percentage of relaxation time breathing at
rates at or less than 10 (p < 0.001), 8 (p < 0.001) and 6 (p < 0.01) breaths per minute after
biofeedback training.
Clinical significance was also analyzed by assigning a letter grade to each
patient’s average breathing rate during the 5-minute self-relaxation of the
psychophysiologic assessment before and after biofeedback training. Table V illustrates
that 80% of patients made clinical improvements in their respiration rate from session
one to session eight.

Inpatients vs. Outpatients
Respiration rate data were also analyzed by patient status (inpatients vs.
outpatients). As shown in Figure 20, there were no significant differences between these
groups (p = 0.86), but both inpatients and outpatients significantly lowered their
respiration rate following biofeedback training. Inpatients went from 15.3 ± 3.5 breaths
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Figure 18. Average respiration rate during self-relaxation across
all biofeedback sessions.
Average respiration rate among patients decreased across sessions,
reaching a significantly lower rate (relative to session 1) in session 4
(p < 0.05) and continued to decrease in session 5 (p < 0.01) and
throughout the remaining three sessions (p < 0.001).
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Figure 19. Percentage of relaxation time patients spent breathing
at lower rates before and after biofeedback training.
Patients spent significantly more time breathing at or less than 10, 8
and 6 breaths per minute, following biofeedback training ( ***p < 0.01
and *** p < 0.001 vs. Before Training).
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Table V. Clinical Analysis of Respiration Rate Before and
After Biofeedback Training
Change in Clinical Rank

Number (%) of Patients

D→A
D→B
C→A
C→B
B→A
No Change

6 (30)
4 (20)
2 (10)
2 (10)
2 (10)
4 (20)

KEY: A = 9 or lower; B = 10-12; C = 13-15; D = 16 or greater breaths per minute
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Figure 20. Average respiration rate during self-relaxation before
and after biofeedback training in inpatients and outpatients.
No significant differences between inpatients and outpatients were
found, but both groups significantly lowered their respiration rate
following biofeedback training (inpatients: p < 0.001 vs. Before
Training; outpatients: p < 0.01 vs. Before Training).
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per minute in session 1 to 9.4 ± 2.6 breaths per minute in session 8 (p < 0.001), and
outpatients went from 14.4 ± 1.8 breaths per minute in session 1 to 9.5 ± 3.0 breaths per
minute in session 8 (p < 0.01).
In the across-sessions analysis, inpatients were able to significantly lower their
respiration rate earlier in biofeedback training than outpatients. As shown in Figure 21,
inpatient breathing rate reached statistical significance by session 4 (p < 0.05), and
outpatients were breathing at a significantly lower rate in session 6 (p < 0.05).
No differences between inpatients and outpatients were found in the percentage of
relaxation time patients met specific criteria (percent counter) analysis. In all cases, both
inpatients and outpatients spent significantly more relaxation time breathing at lower
rates after biofeedback training (p-values vs. before training are shown in Table VI).

Digital Peripheral Temperature
In addition to respiration rate, digital peripheral temperature was also analyzed
before and after biofeedback training as well as across all biofeedback sessions. Figure
22 shows that there were no significant changes in finger temperature following
biofeedback training (p = 0.72) or across biofeedback sessions (overall p-value = 0.99).
Two patients were able to make a clinically significant improvement in finger
temperature, moving from a range of 80-90°F in session 1 to ≥ 90°F in session 8.

Inpatients vs. Outpatients
No significant differences in temperature were found between inpatients and
outpatients following biofeedback training (p = 0.34) or across biofeedback sessions (IP:
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Figure 21. Average respiration rate during self-relaxation across
all biofeedback sessions in inpatients and outpatients.
With respect to session 1, inpatients (A) were able to lower respiration
significantly in session 4 (p < 0.05), and outpatients (B) significantly
lowered respiration rate in session 6 (p < 0.05).
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Table VI. Respiration Rate Percent Counter Summary for Inpatients and
Outpatients
≤ 10 breaths per minute

≤ 8 breaths per minute

≤ 6 breaths per minute

IPs

OPs

IPs

OPs

IPs

OPs

p < 0.001

p < 0.01

p < 0.01

p < 0.01

p < 0.05

p < 0.05

The p-values shown are vs. before training.
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Figure 22. Average finger temperature following and throughout
biofeedback training.
Digital peripheral temperature did not change significantly (A)
following biofeedback training (p = 0.72) or (B) across biofeedback
sessions (p = 0.99).
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p = 0.63; OP: p = 0.94). Of the two patients who made clinical improvements in their
finger temperature, one was an inpatient, and one was an outpatient.

Skin Conductance
Due to safety precautions, skin conductance sensors were not used in patients who
had a pacemaker. As a result, skin conductance was only able to be measured in two
patients (both inpatients), and therefore it was analyzed across biofeedback sessions only.
No significant changes were made in skin conductance throughout biofeedback sessions
(p = 0.39) as shown in Figure 23, but the average skin conductance value at each session
was below 2µS, a value that represents relaxed physiology.

Heart Rate Variability
The standard deviation of the inter-beat interval (SDNN) during the 5-minute selfrelaxation of each session was calculated and compared before and after biofeedback
training as well as across all biofeedback sessions. Figure 24 shows that average SDNN
increased significantly after biofeedback training (p < 0.05), from 32 ± 22 milliseconds to
44 ± 23 milliseconds. On an individual basis, 5 out of 20 patients (25%) increased their
SDNN from an unhealthy range (0-50 msec) to a moderately healthy range (50-100
msec), as defined by the Task Force of the European Society of Cardiology and the North
American Society of Pacing Electrophysiology.110
When analyzing SDNN across all biofeedback sessions, 5 patients were dropped
from the analysis because there was missing data in one of their eight sessions, and
therefore these 5 patients could not be included in a repeated measures analysis of
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Figure 23.
Average skin conductance during self-relaxation
across all biofeedback sessions.
Skin conductance (n = 2) did not change significantly across
biofeedback sessions (p = 0.39).
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Figure 24. Average SDNN during self-relaxation before and after
biofeedback training.
On average, patients’ SDNN increased from 32 ± 22 msec to 44 ± 23
msec following biofeedback training (p < 0.05 vs. Before Training).
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variance. The across-sessions analysis of the 15 remaining patients for which all data
were present showed that SDNN increased significantly across sessions (overall p-value
= 0.03), as shown in Figure 25.
SDNN data were also analyzed across sessions using all 20 patients (1) by
replacing missing values with the same value as the previous session and (2) by replacing
missing values with an average of the values from the session before and after the
missing session, but neither of these analyses showed a significant change over time ((1)
p = 0.09; (2) p = 0.37).

Inpatients vs. Outpatients
When the SDNN data (n = 15) was separated by patient status, no significant
differences were found before and after biofeedback training (p = 0.69). Although not
significant, outpatient SDNN before training (24 ± 18 msec) was lower than inpatient
SDNN before training (37 ± 24 msec) (Figure 26).

Across biofeedback sessions,

outpatients showed a significant increase in SDNN (overall p-value = 0.01) that was not
present in the inpatient sample (p = 0.62) (Figure 27).

Psychophysiologic Reactivity and Recovery
In order to assess the effects of biofeedback-assisted stress management training
on patients’ response to mental stress, instantaneous heart rate was analyzed before,
during and after each mental stress task in the psychophysiologic assessment before and
after biofeedback training. Figure 28 shows that there was no significant difference in
baseline heart rate prior to the start of either psychophysiologic assessment (p = 0.45).
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Figure 25.
Average SDNN during self-relaxation across all
biofeedback sessions.
SDNN (n = 15) increased significantly across sessions (overall p-value
= 0.03).
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Figure 26. Average SDNN during self-relaxation before and after
biofeedback training in inpatients and outpatients.
Outpatient (n = 7) SDNN before training, while not significant (p =
0.32), is lower than inpatient (n = 8) SDNN before training.
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Figure 27.
Average SDNN during self-relaxation across all
biofeedback sessions in inpatients and outpatients.
(A) Inpatients (n = 8) did not change SDNN across biofeedback
sessions (p = 0.62). (B) Outpatients (n = 7) significantly increased
SDNN across biofeedback sessions (p = 0.01).
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Figure 28. Average heart rate during five-minute baseline in
psychophysiologic assessment before and after biofeedback
training.
Baseline heart rate was not significantly different in the
psychophysiologic assessment before and after biofeedback training (p
= 0.45).
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Cardiovascular reactivity to each stressor was measured by subtracting the
average heart rate before the stressor from the average heart rate during the stressor, and
both absolute change and percent change were analyzed.

Following biofeedback

training, cardiovascular reactivity (absolute change) decreased in response to the Stroop
Color Word Test (5.5 ± 8.5 to 3.8 ± 7.3 beats per minute) and increased in response to the
Serial Sevens (2.5 ± 8.4 to 3.5 ± 7.6 beats per minute) and Stressful Event Recall (4.9 ±
8.8 to 8.4 ± 6.8 beats per minute) tasks, however none of these changes reached statistical
significance (p = 0.34, 0.87, and 0.16, respectively).
Using this same method of calculating absolute change in cardiovascular
reactivity, trends were established for each stressor, and the results are summarized in
Table VII. Overall, not counting the patients whose reactivity did not change, about half
the remaining patients reacted less to mental stress following biofeedback training, and
about half the patients reacted more.
The most reliable measure of cardiovascular reactivity is an aggregate percent
change score calculated by adding the percent change response for all three stressors and
comparing this value before and after biofeedback training.70 Figure 29 shows that
overall, cardiovascular reactivity did not change after biofeedback training (p = 0.86).
Recovery from mental stress was also evaluated by subtracting the average heart
rate before each stressor from the average heart rate after the stressor. Absolute and
percent change scores were calculated, with positive values indicating that the baseline
heart rate had not been reached (average heart rate after the stressor still higher than the
average heart rate before the stressor), and negative scores indicating that the baseline
heart rate had been surpassed (average heart rate after the stressor was even lower than
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Table VII. Trends in Cardiovascular Reactivity

Stroop
Math
Recall

Reacted Less
After Training

No Change
in Reactivity

Reacted More
After Training

9
6
9

4
4
2

7
10
9

24 / 60 (40%)

10 / 60 (17%)

26 / 60 (43%)
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Figure 29.
Overall cardiovascular reactivity to mental stress
following biofeedback training.
There was no significant change in cardiovascular reactivity to mental
stress following biofeedback training (p = 0.86). Data are expressed
as an aggregate percent change.
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the average heart rate before the stressor).
Following biofeedback training, patients recovered less from the Stroop Color
Word Test (0.23 ± 3.7 to 1.8 ± 5.0 beats per minute) and more from the Serial Sevens (0.41 ± 4.3 to -1.8 ± 6.3 beats per minute) and Emotional Event Recall (-5.6 ± 7.1 to -8.1
± 7.3 beats per minute) stressors, however none of these changes were significant (p =
0.39, 0.78, and 0.30, respectively).

The percent change aggregate recovery data

(calculated by adding the percent change response for all recoveries), shown in Figure
30, also indicates that there was no significant change in cardiovascular recovery from
mental stress following biofeedback training (p = 0.28).

Inpatients vs. Outpatients
When the data were separated into inpatients and outpatients, no significant
differences were found in average baseline heart rate prior to mental stress before or after
biofeedback training (p = 0.97).
Figure 31 shows the aggregate percent change scores for cardiovascular reactivity
and recovery separated by patient status. Although not significant (p = 0.24), inpatients
reacted more to mental stress following biofeedback training, and outpatients reacted
less. With respect to cardiovascular recovery, overall results were significant (p = 0.01);
inpatients recovered from mental stress more than outpatients.

3.2 Homework Data
Table VIII shows the number of homework sheets that were turned in by each
patient. The patients on the right in bold type are those who completed all eight sessions
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Percent Change in Heart Rate (%)

3
2
1
0
-1
-2
Before Training

After Training

Figure 30. Overall cardiovascular recovery from mental stress
following biofeedback training.
There was no significant change in cardiovascular recovery from
mental stress following biofeedback training (p = 0.28). Data are
expressed as an aggregate percent change.
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B

Percent Change in Heart Rate (%)
Percent Change in Heart Rate (%)

A

50

Before Training
After Training

40
30
20
10
0
Inpatients

Outpatients

6

Before Training
After Training

4
2
0
-2
-4
Inpatients

Outpatients

Figure 31. Overall cardiovascular reactivity and recovery before
and after biofeedback training in inpatients and outpatients.
Cardiovascular reactivity to mental stress (A) increased in inpatients
and decreased in outpatients following biofeedback training, although
the differences were not statistically significant. Cardiovascular
recovery from mental stress (B) was significantly greater in inpatients
relative to outpatients (p = 0.01).
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Table VIII. Number of Homework Sheets Turned In
IP 2
IP 5
IP 6
IP 9
IP 12
IP 13
IP 19
IP 20
IP 21
OP 2

2
4
0
0
0
0
0
6
9
0

OP 4
OP 5
OP 6
OP 10
OP 14

2
0
0

IP 1
IP 3
IP 4
IP 7
IP 8
IP 10
IP 11
IP 14
IP 15
IP 16

5
23
3
0
12
0
0
6
0
0

IP 17
IP 18
OP 1
OP 3
OP 7
OP 8
OP 9
OP 11
OP 12
OP 13

Patients highlighted in bold type are the 20 patients who completed all 8 sessions of biofeedback
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0
5
34
34
28
17
34
16
4
12

of biofeedback.
The 20 patients who completed all eight sessions of biofeedback were put into
quartiles based on the number of homework sheets they turned in, and as shown in
Figure 32, outpatients did more homework than inpatients. This result reached statistical
significance when the average number of homework sheets turned in was compared.
Inpatients turned in 5 ± 7 sheets, and outpatients turned in 22 ± 12 sheets (p < 0.01).

3.3 Quality of Life Data
SF-36
Table IX lists the mean of each SF-36 aggregate score before and after
biofeedback training and its corresponding p value. Note that aggregate scores are out of
100, and an increase in score reflects a greater level of functioning. No significant
differences were found.

Inpatients vs. Outpatients
Each aggregate score was also separated by patient status, and eight out of ten
scores did not show any significant differences.

As shown in Figures 33 and 34

respectively, inpatients had a lower social functioning score (p < 0.05) and a greater
general health score (p < 0.05) when compared to outpatients.
The eight aggregate scores for which clinically important differences have been
established123 are shown in Table X. For both inpatients and outpatients, some changes
in aggregate scores reflected clinical improvement and some reflected clinical regression.
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Number of Patients

8

Inpatients
Outpatients

6
4
2
0
1

2

3

4

Quartiles
Quartile
Quartile
Quartile
Quartile

1
2
3
4

=
=
=
=

0
1
6
≥

sheets turned in
- 5 sheets turned in
- 20 sheets turned in
21 sheets turned in

Figure 32.
Quartile distribution of homework turned in by
inpatients and outpatients.
Outpatients turned in more homework than inpatients. This difference
was statistically significant when the average number of homework
sheets turned in was compared. On average, inpatients turned in 5 ± 7
sheets, and outpatients turned in 22 ± 12 sheets (p < 0.01).
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Table IX. Aggregate Scores on SF-36 Before and After Biofeedback Training
Before
Biofeedback Training

After
Biofeedback Training

p - value

Physical Functioning

29.5 ± 22.4

30.5 ± 22.35

0.72

Role Limitations (Physical)

10.5 ± 25.4

11.8 ± 21.0

0.71

Role Limitations (Emotional)

45.0 ± 43.6

38.3 ± 43.6

0.35

Energy / Fatigue

34.4 ± 19.8

40.1 ± 25.0

0.17

Emotional Well-Being

67.5 ± 20.0

68.8 ± 18.1

0.76

Social Functioning

48.2 ± 31.5

50.8 ± 30.7

0.20

Pain

58.5 ± 25.6

65.6 ± 24.0

0.22

General Health

34.4 ± 19.3

35.8 ± 21.4

0.45

PHYSICAL SUMMARY

28.2 ± 5.89

29.8 ± 7.59

0.23

MENTAL SUMMARY

46.1 ± 10.8

46.1 ± 10.8

0.97

Aggregate Score

Score data are presented as average ± standard deviation
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SF-36 Social Functioning Score

100

Before Training
After Training

80
60
40
20
0
Inpatients

Outpatients

Figure 33. SF-36 social functioning aggregate score before and
after biofeedback training in inpatients and outpatients.
Inpatients reported lower social functioning than outpatients (p <
0.05), and this did not change with biofeedback training.
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SF-36 General Health Score
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Before Training
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80
60
40
20
0
Inpatients

Outpatients

Figure 34. SF-36 general health aggregate score before and after
biofeedback training in inpatients and outpatients.
Inpatients reported greater general health relative to outpatients (p <
0.05), and this did not change with biofeedback training.
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Table X. Clinical Analysis of SF-36 Aggregate Scores
SF-36
Summary Score

PF

RLP

Minimal
Clinical Improvement

1 IP

1 IP
3 OP

Moderate
Clinical Improvement

1 IP

Large
Clinical Improvement

1 IP

2 IP

Minimal
Clinical Decline

1 OP

1 OP

Moderate
Clinical Decline

1 IP

Large
Clinical Decline

RLE

EF

EWB

SF

P

GH

1 IP

1 IP
1 OP

2 IP
2 OP

3 IP
2 OP

3 IP
2 OP

1 IP

1 IP
1 OP

2 IP

1 IP

1 IP
1 OP

3 IP
1 OP

1 IP
3 OP

1 IP
1 OP

1 IP

1 IP
1 OP

1 OP

1 IP
1 OP

1 IP

PF = Physical Functioning, RLP = Role Limitations (Physical), RLE = Role Limitations (Emotional), EF = Energy / Fatigue,
EWB = Emotional Well-Being, SF = Social Functioning, P = Pain, GH = General Health, IP = Inpatient, OP = Outpatient
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Kansas City Cardiomyopathy Questionnaire
Table XI lists the mean of each Kansas City Cardiomyopathy (KCCM) aggregate
score before and after biofeedback training and its corresponding p-value. Once again
the aggregate scores are out of 100, and an increase in score reflects a greater level of
functioning. Note that no significant differences were found.

Inpatients vs. Outpatients
KCCM aggregate scores were also separated by patient status, and eight out of ten
summary scores did not show any significant differences. Figures 35 and 36 show that
inpatients had a lower quality of life score (p < 0.01) and a higher clinical summary score
(p < 0.05) relative to outpatients.
Clinically significant differences in each of the ten KCCM summary scores are
outlined in Table XII and separated by patient status. Clinical improvement and clinical
decline were seen among aggregates for both inpatients and outpatients.

3.4 Subjective Data
Throughout both psychophysiologic assessments, patients were asked to report
their level of relaxation after each activity (self-relaxation, stressors and subsequent rests)
using a 5-point Likert scale with 1 being not at all relaxed and 5 being completely
relaxed.

As shown in Figure 37, patients felt significantly more relaxed after

biofeedback training for every psychophysiologic assessment activity except for the selfrelaxation (p = 0.15) and the stressful event recall (p = 0.13).
Psychophysiologic assessment activities were also grouped into stressors and
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Table XI. Aggregate Scores on KCCM Before and After Biofeedback Training
Before
Biofeedback Training

After
Biofeedback Training

p - value

Physical Limitation

42.8 ± 22.5

46.7 ± 22.4

0.25

Symptom Stability

56.5 ± 16.3

55.2 ± 19.6

0.82

Symptom Frequency

61.2 ± 22.8

64.3 ± 24.1

0.41

Symptom Burden

66.6 ± 19.5

65.8 ± 22.6

0.84

Total Symptom

64.0 ± 20.2

65.0 ± 22.1

0.77

Self-Efficacy

85.7 ± 17.7

92.0 ± 11.5

0.16

Quality of Life

40.4 ± 19.7

40.3 ± 22.6

0.97

Social Limitation

32.7 ± 28.4

28.1 ± 19.9

0.60

OVERALL SUMMARY

47.4 ± 14.1

47.5 ± 13.3

0.96

CLINICAL SUMMARY

57.1 ± 16.2

59.4 ± 16.9

0.49

Aggregate Score
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KCCM Quality of Life Score

100

Before Training
After Training

80
60
40
20
0
Inpatients

Outpatients

Figure 35. KCCM quality of life aggregate score before and after
biofeedback training in inpatients and outpatients.
Overall, inpatients reported a lesser quality of life than outpatients (p <
0.01), and this did not change with biofeedback training.
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KCCM Clinical Summary Score
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80
60
40
20
0
Inpatients

Outpatients

Figure 36. KCCM clinical summary aggregate score before and
after biofeedback training in inpatients and outpatients.
Inpatient clinical summary score was higher than outpatient clinical
summary score (p < 0.05), and this did not change with biofeedback
training.
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Table XII. Clinical Analysis of KCCM Aggregate Scores
KCCM
Summary Score

PL

SS

SF

SB

TSS

SE

QOL

SL

OSS

CSS

Clinical Improvement

5 IP
4 OP

1 IP
2 OP

6 IP
3 OP

6 IP
3 OP

6 IP
3 OP

4 IP
3 OP

6 IP
3 OP

3 IP
1 OP

6 IP
0 OP

6 IP
4 OP

No Change

6 IP
1 OP

7 IP
4 OP

3 IP
3 OP

3 IP
1 OP

4 IP
2 OP

6 IP
4 OP

3 IP
1 OP

4 IP
3 OP

0 IP
6 OP

3 IP
0 OP

Clinical Decline

1 IP
3 OP

3 IP
2 OP

3 IP
2 OP

3 IP
4 OP

2 IP
3 OP

2 IP
1 OP

3 IP
4 OP

3 IP
4 OP

4 IP
2 OP

1 IP
4 OP

PL = Physical Limitation, SS = Symptom Stability, SF = Symptom Frequency, SB = Symptom Burden, TSS =
Total Symptom Score, SE = Self-Efficacy, QOL = Quality of Life, SL = Social Limitation, OSS = Overall Summary
Score, CSS = Clinical Summary Score, IP = Inpatient, OP = Outpatient
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Figure 37.
Self-reported relaxation level throughout psychophysiologic assessment before and after biofeedback training.
Patients
reported
being
more
relaxed
throughout
the
psychophysiologic assessment following biofeedback training ( * p <
0.05 and ***p < 0.01).
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relaxing activities. This analysis showed that patients reported being more relaxed after
relaxing activities than stressful activities (p < 0.01), independent of biofeedback training.
Grouped activities were then analyzed before and after biofeedback training, and Figure
38 shows that patients were significantly more relaxed after biofeedback training for both
stressful activities (p < 0.001) and relaxing activities (p < 0.01).
The same relaxation Likert scale was used to gauge patients’ relaxation levels at
the beginning and the end of each training session. Figure 39 shows that patients were
more relaxed at the end of training sessions than they were at the beginning.
A similar 5-point Likert scale was used to evaluate patients’ mood at the
beginning and end of each training session. On this Likert mood scale, 1 represented sad,
and 5 represented happy. Figure 40 shows that patients reported being in a better mood
at the end of biofeedback training sessions.

Inpatients vs. Outpatients
Both inpatients and outpatients reported feeling more relaxed after biofeedback
training for each psychophysiologic assessment activity.

The difference reached

statistical significance for inpatients with respect to the Serial Sevens (p < 0.05), Rest #2
(p < 0.01) and Rest #3 (p < 0.05) activities. Significantly greater relaxation for the
outpatients was reported following the Stroop Color Word Test (p < 0.05).
In the grouped analysis of psychophysiologic assessment activities, there was no
difference between inpatient and outpatient responses to stressors (p = 0.31) or to
relaxing activities (p = 0.32). In both cases, a significant training effect was shown. Both
inpatients and outpatients reported being more relaxed after biofeedback training with
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Level of Relaxation
(1 = Not at all relaxed;
5 = Completely relaxed)

5
4

**

***

Before Training
After Training

3
2
1
Stressors

Relaxation

Figure 38.
Self-reported relaxation level for stressful and
relaxing psychophysiologic assessment activities before and after
biofeedback training.
Patients reported being more relaxed following biofeedback training
for both stressful ( *** p < 0.001) and relaxing ( ***p < 0.01) activities
of the psychophysiologic assessment.
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Relaxation Level 1 Relaxation Level 2 Relaxation Level 3 Relaxation Level 4 -
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Figure 39.
Average self-reported relaxation level throughout
training sessions.
On average, patients reported being more relaxed at the end of
biofeedback training sessions than at the beginning.
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Figure 40.
sessions.

Average self-reported mood throughout training

On average, patients reported being in a better mood at the end of
biofeedback training sessions than at the beginning.
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2
3
4
5

respect to both stressors (overall p-value = 0.002) and relaxing activities (overall p-value
= 0.003). These relationships were only significant for inpatients, however. Inpatients
were significantly more relaxed after stressors and relaxing activities after biofeedback
training (both stressor and relaxing activity p-values < 0.05).

3.5 Clinical Data
Clinical data were collected in outpatients only. As a reference for the remaining
analyses, Table XIII provides a checklist for what data were collected on each patient in
the study. Patients who completed all eight sessions of biofeedback are highlighted in
gray.

Six Minute Walk Test
Patients (n = 7) walked an average of 910 ± 421 feet before biofeedback training
and 961 ± 318 feet after biofeedback training (p = 0.81) as shown in Figure 41. For
patients with heart failure, 130 feet is the clinical cut-off for improvement or regression
in functional capacity,3,91 and when analyzed as individuals using this criterion, Figure
42 shows that three patients (highlighted in red, blue and green) made clinical
improvements in their six-minute walk distance (red: 1080 to 1270 feet; blue: 420 to 690
feet; green: 200 to 500 feet).

Plasma Norepinephrine
Figure 43 shows that patients’ average plasma norepinephrine level (n = 8) was
501 ± 312 pg/mL before biofeedback training and 470 ± 288 pg/mL after biofeedback
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Table XIII. Data Collected on All Patients Enrolled in the Study
PT ID

SA #1

#T

SA #2

6MW

NE

SF-36

KCCM

Tx

M

R

W

IP 1
IP 2
IP 3
IP 4
IP 5
IP 6
IP 7
IP 8
IP 9
IP 10
IP 11
IP 12
IP 13
IP 14
IP 15
IP 16
IP 17
IP 18
IP 19
IP 20
IP 21
OP 1
OP 2
OP 3
OP 4
OP 5
OP 6
OP 7
OP 8
OP 9
OP 10
OP 11
OP 12
OP 13
OP 14

X
6
X
X
X
X
X X X
X
4
X
X X X
X
6
X
X
X
X
X X X
X
6
X
X
X
X
X X X
X
2
X
X
4
X
X X X
X
6
X
X
X
X
6
X
X
X X X
X
1
X
6
X
X
X
X
6
X
X
X
X
X
X
1
X
X
4
X
6
X
X
X
6
X
X
X
X
X X X
X
6
X
X
X
X
6
X
X
X
X
6
X
X
X
X
0
X
X
5
X
X X X
X
4
X
X X X
X
6
X
X
X
X
X
5
X
X X X
X
6
X
X
X
X
X
Consented, but never returned our call to schedule his first appointment…
X
4
Consented, but received a heart transplant before his first appointment…
X
6
X
X
X
X
X
X
6
X
X
X
X
X
X
6
X
X
X
X
X
X
1
X
6
X
X
X
X
X
X
6
X
X
X
X
X
X
6
X
X
X
X
X
X
2
X

IP = Inpatient; OP = Outpatient; SA = Stress Assessment (#1 - Before Biofeedback; #2 - After
Biofeedback); #T = Number of Training Sessions Completed; 6MW = Six Minute Walk Test; NE = Plasma
Norepinephrine; SF-36 = Short-Form 36; KCCM = Kansas City Cadiomyopathy Questionnaire; Tx = Heart
Transplant; M = Muscle Function Experiments; R = Beta / Muscarinic Receptors; W = Western Blots
Note: Biological experiments were done if the patient had at least 4 out of 6 biofeedback training sessions
before receiving a heart transplant.
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Figure 41. Average six minute walk distance before and after
biofeedback training.
Average six minute walk distance did not change following
biofeedback training (n = 7; p = 0.81).
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Figure 42. Individual six minute walk distance before and after
biofeedback training.
Three patients (highlighted in red, blue and green) made clinical
improvements in six minute walk distance following biofeedback
training.

96

Plasma Norepinephrine (pg/mL)

1500

1000

500

0
Before Training

After Training

Figure 43. Average plasma norepinephrine level before and after
biofeedback training.
Average norepinephrine level did not change following biofeedback
training (n = 8; p = 0.72).
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training (p = 0.72).

Although not the same three patients who made clinical

improvements in their six minute walk distance, another three patients’ plasma
norepinephrine levels decreased (improved) following biofeedback training as shown in
Figure 44 (red: 1192 to 701 pg/mL; blue: 352-175; green: 296-189).

3.6 Biological Data
Tables XIV and XV display detailed and summarized patient demographics,
respectively, for the groups analyzed in the biological experiments. A total of 47
patients were studied, including 12 donors (non-failing – NF), 12 heart failure patients
(failing), 12 heart failure patients who were hemodynamically supported with a left
ventricular assist device prior to heart transplant (F + LVAD), and 11 heart failure
patients who received biofeedback-assisted stress management training (F + biofeedback)
prior to cardiac transplantation. Average age among groups ranged from 48 to 56 years
old, with the majority of patients being white males with dilated cardiomyopathy.
Average left ventricular ejection fraction for patients in the non-failing group was 61%,
and for the three failing groups, average LVEF ranged from 12-19%.

Muscle Function
Muscle function experiments were conducted in order to test the response of
freshly dissected trabecular muscles to sympathetic nervous system (beta-adrenergic)
stimulation. This was accomplished by adding a synthetic analogue of norepinephrine,
called isoproterenol (ISO), to the muscles and measuring various contractile parameters.
In order to ensure that the contractile responses measured were due to our experimental
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Figure 44. Individual plasma norepinephrine level before and
after biofeedback training.
Three patients (highlighted in red, blue and green) had decreased
levels of plasma norepinephrine following biofeedback training.
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Table XIV. Detailed Patient Demographics for Biological Data
Status/Diagnosis
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
F
F
F
F
F
F
F
F
F
F
F
F
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + LVAD
F + BF
F + BF
F + BF
F + BF
F + BF
F + BF
F + BF
F + BF
F + BF
F + BF
F + BF

Age
71
53
44
18
20
61
60
16
59
NA
67
54
66
61
58
60
66
65
61
63
44
50
46
26
62
61
59
52
27
58
64
57
51
44
42
64
58
58
60
53
66
46
21
65
62
66
58

Sex
M
F
F
M
M
M
F
F
M
NA
F
M
M
M
M
F
M
M
M
F
M
M
M
M
M
F
M
M
M
M
M
M
M
M
M
M
M
M
M
F
M
M
M
M
M
M
M

Race
W
B
W
W
W
NA
W
W
W
NA
W
W
O
W
W
W
W
H
W
B
B
W
B
W
W
B
W
W
W
W
W
W
W
W
W
W
W
W
W
B
W
W
H
W
B
W
W

LVEF
NA
NA
57
"depressed EF"
57
NA
65
NA
NA
NA
65
63
15
10
20
10
NA
15
25
10
50
20
25
10
13
NA
20
NA
5
10
15
10
15
NA
10
10
25
15
15
15
10
60
10
20
10
15
15

Patients who were added to Muscle Function and Western Blot Analyses
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Table XV. Summarized Patient Demographics for Biological Data
Group

Age

Sex

Race

LVEF

Diagnosis

Donor

48

6M
5F
1 UNK

9W
1B
2 UNK

61

-

Failing

56

10 M
2F

7W
3B
1H
1 "other"

19

8 DCM
4 ICM

LVAD

53

11 M
1F

11 W
1B

12

7 DCM
5 ICM

Biofeedback

56

10 M
1F

8W
2B
1H

19

7 DCM
3 ICM
1 CONG

M = Male; F = Female; UNK = Unknown; W = White; B = Black; H = Hispanic; DCM =
Dilated Cardiomyopathy; ICM = Ischemic Cardiomyopathy; CONG = Congenital
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manipulation (adding isoproterenol) and not to underlying differences in muscle function,
contractile parameters were measured at baseline, and they can be found in Table XVI.
No significant differences were found among groups for any of the six parameters.
These same six contractile parameters were also measured following the addition
of ISO, and results were compared among groups as a percent change from baseline.
Data from the F + BF group were also analyzed on an individual patient basis. Figure 45
shows that there were no significant differences among groups with respect to the resting
tension response (RT) (p = 0.06), and RT for 9 out of 11 patients in the F + BF group is at
or approaching non-failing levels.
Developed tension (DT) results are depicted in Figure 46, and as we expected,
muscles from failing hearts improved contraction less than muscles from non-failing
hearts in response to beta-adrenergic stimulation (p < 0.01), and this response recovered
in the F + LVAD group. Although not to the same extent as muscles from the F + LVAD
group, the F + BF muscles also recovered such that there was no significant difference
between the F + BF group and the non-failing group. On an individual patient basis,
three patients in the F + BF showed a developed tension response at the non-failing level
(IP 4, IP 6, and IP 8), and five patients’ DT response fell somewhere in between failure
and non-failure (IP 2, IP 3, IP 15, IP 20 and IP 21). The last three patients in the F + BF
group had a DT response to isoproterenol that was at the failing level (IP 1, IP 11 and OP
2).
Figure 47 shows the time to peak tension (TPT) results.

No significant

differences were found among groups (p = 0.70), and although the non-failing and failing
means are so similar (-23.4% and -22.0%, respectively), the individual patient data from
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Table XVI. Contractile Parameters at Baseline
Contractile Parameters

NF

Failing

F + LVAD

F + BF

3.11 ± 0.38

2.75 ± 0.30

2.51 ± 0.33

2.04 ± 0.15

DT (g/mm )

1.12 ± 0.15

0.99 ± 0.15

1.69 ± 0.25

0.72 ± 0.15

TPT (sec)

0.18 ± 0.01

0.18 ± 0.01

0.19 ± 0.01

0.17 ± 0.00

RT (g/mm2)
2

0.14 ± 0.00

0.14 ± 0.01

0.14 ± 0.01

0.13 ± 0.00

2

+dT/dt (g/sec/mm )

9.11 ± 1.26

10.41 ± 1.31

11.06 ± 1.40

7.70 ± 1.35

-dT/dt (g/sec/mm2)

7.66 ± 1.25

8.85 ± 1.19

9.76 ± 1.19

6.28 ± 1.33

THR (sec)

NF = Non-failing; F + LVAD = Failing + Left Ventricular Assist Device; F + BF = Failing + Biofeedback; RT = Resting
Tension; DT = Developed Tension; TPT = Time to Peak Tension; THR = Time to Half Relaxation; +dT/dt = Peak
Rate of Tension Rise; -dT/dt = Peak Rate of Tension Fall
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Figure 45. Resting tension following addition of isoproterenol.
(A) No significant differences were found among groups for the
resting tension response to isoproterenol (p = 0.06), and (B) the
majority of patients in the F + BF group had muscles with resting
tension levels at or near non-failing muscles.
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Figure 46. Developed tension following addition of isoproterenol.
(A) Muscles taken from failing hearts contracted significantly less
than muscles taken from non-failing hearts in response to
isoproterenol (p < 0.05). (B) Muscles taken from three patients in the
F + BF group contracted at non-failing levels in response to
isoproterenol, and five others contracted more than the average of
muscles in the failing group.
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the F + BF group showed that three patients have TPT responses that are at or surpass the
non-failing level.
The results of time to half relaxation (THR) analyses did not show any significant
differences among groups (p = 0.11) as shown in Figure 48. The individual analysis of
patients in the F + BF group showed that the THR response for most of the muscles was
like that of muscles taken from non-failing hearts, but again, the means from the nonfailing (-30.3%) and failing (-33.4%) groups are very similar.
Figure 49 shows that peak rate of tension rise (+dT/dt) was lower in the failing
group relative to muscles taken from non-failing hearts (p < 0.01). This response was not
seen in the F + LVAD or F + BF groups, both of which did not differ significantly from
the non-failing group. Also, the three patients in the F + BF group who had a developed
tension response to isoproterenol that was equivalent to that of muscles from non-failing
hearts (IP 4, IP 6 and IP 8) were also the three patients whose peak rate of tension rise
response was at or above the non-failing level.
The peak rate of tension fall (-dT/dt) results were very much like peak rate of
tension rise. As Figure 50 shows, peak rate of tension fall was lower in the failing group
relative to the non-failing group (p < 0.01). Both the F + LVAD group and the F + BF
group were not significantly different from non-failing hearts. On an individual patients
basis, muscles taken from hearts of F + BF inpatients 4, 6 and 8 again looked like
muscles from the non-failing group with respect to –dT/dt.

Beta-Adrenergic Receptors
To further explore the sympathetic nervous system pathway, beta-adrenergic
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Figure 48. Time to peak half relaxation following addition of
isoproterenol.
(A) No significant differences were found among groups for time to
half relaxation (p = 0.11), and (B) the majority of patients in the F +
BF group had muscles with time to half relaxation levels at or near
non-failing muscles.
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Peak rate of tension rise following addition of
isoproterenol.
(A) Muscles taken from failing hearts had a lower peak rate of tension
rise in response to isoproterenol (p < 0.01) relative to non-failing
hearts. (B) Muscles taken from three patients in the F + BF group had
peak rate of tension rise responses at the level of non-failing muscles.
These were the same three patients whose developed tension response
was also at or above the non-failing level.
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Figure 50.
Peak rate of tension fall following addition of
isoproterenol.
(A) Muscles taken from failing hearts had a lower peak rate of tension
fall in response to isoproterenol (p < 0.01) relative to non-failing
hearts. (B) Muscles taken from three patients in the F + BF group had
peak rate of tension fall responses at the level of non-failing muscles.
These were the same three patients whose developed tension and peak
rate of tension rise responses were also at or above the non-failing
level.
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receptors were measured among non-failing (NF), failing, F + LVAD and F + BF groups.
Once again, our group of interest, the F + BF group, was also analyzed on an individual
patient basis. As shown in Figure 51, beta receptor density was significantly lower in
failing hearts (p < 0.05) and recovered in failing hearts with LVAD support. Beta
receptor density in the F + BF group did not recover like the F + LVAD group, but rather
was significantly less than that of the non-failing hearts (p < 0.05). Individually, three
patients in the F + BF group showed beta receptor recovery at the non-failing level (IP 1,
IP 8 and IP 15). Only one of these patients (IP 8) was one of the patients whose
developed tension response to isoproterenol was also at the non-failing level.
Binding affinity for beta-adrenergic receptors was also analyzed among groups by
measuring the dissociation constant (Kd), and Figure 52 shows that no significant
differences were found (p = 0.06).

The overall p-value was very close to being

significant, and groups with the lowest and highest mean Kd were the F + LVAD (31.4 ±
12.9 pM) and F + BF group (52.3 ± 21.8), respectively. Individual patient analysis for
the F + BF group showed that half of the patients had a Kd that was 40pM or below, and
the other half of the patients had a Kd that was much higher, at 60pM or above.

Muscarinic Receptors
To analyze the contribution of the parasympathetic nervous system, muscarinic
receptor density and Kd were also measured.

As shown in Figure 53, muscarinic

receptor density was significantly higher in the failing (p < 0.01) and F + LVAD (p <
0.001) groups relative to NF hearts. There was no difference between the NF and F + BF
groups. With the exception of one statistical outlier, highlighted in white, most patients

111

60

40

20

0
Failing

F + LVAD

F + BF

60

NF
40

Failing
20

2

O
P

21

20

IP

15

IP

6

8

IP

IP

IP

4

2

3
IP

IP

1

0
IP

Density (fmol/mg protein)

NF

B

*

*

IP

Density (fmol/mg protein)

A

Figure 51. Beta-adrenergic receptor density.
(A) The density of beta-adrenergic receptors was significantly lower in
the failing and F + BF groups compared to beta receptor density in
non-failing hearts (p < 0.05). (B) Three patients in the F + BF group
showed beta-adrenergic receptor densities at the non-failing level.
Only one of these patients was also one whose developed tension
response to isoproterenol was also at the non-failing level.
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Figure 52. Binding affinity for beta-adrenergic receptors.
(A) Beta-adrenergic receptor Kd was not significantly different among
groups (p = 0.06). (B) Half of the patients in the F + BF group had
Kd’s that were much higher than the other half of patients.
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Figure 53. Muscarinic receptor density.
(A) Muscarinic receptor density was significantly higher in the failing
(p < 0.01) and F + LVAD (p < 0.001) groups relative to non-failing
hearts. The F + BF group was not significantly different from the nonfailing group. (B) Most patients in the F + BF group had muscarinic
receptor densities at or just above the non-failing level. IP 15 is an
outlier.

114

in the F + BF group had muscarinic receptor densities at or just above the non-failing
level.
Figure 54 shows that no significant differences were found among groups with
respect to binding affinity for muscarinic receptors (p = 0.07). This Kd data almost did
reach statistical significance, with the highest and lowest mean Kd’s coming from the
non-failing (119.9 ± 33.8 pM) and F + LVAD (230.1 ± 112.9 pM) groups. In the F + BF
group, most muscarinic receptor Kd’s were at or just below the mean of the non-failing
group, with the exception of two much higher values and one outlier Kd of 405.6 pM.

Calcium-Cycling Proteins
With calcium being a vital component of muscle contraction, proteins that help to
cycle calcium in and out of the sarcoplasmic reticulum and in and out of the cell itself
were measured. In all cases, calcium-cycling proteins were normalized to calsequestrin,
a protein that has been shown not to change in heart failure.27,53,83
Figure 55 shows that no significant differences were found among groups with
respect to the sarcoendoplasmic reticulum calcium ATP-ase (SERCA) protein (p = 0.62).
Variable levels of SERCA protein were found in the F + BF group.
No significant differences among groups were found in sodium-calcium
exchanger (NCX) protein levels (p = 0.73), as shown in Figure 56, and the F + BF group
presented with variable NCX levels, most of which were at or above the non-failing
average.
With average values of 0.47 ± 0.19, 0.27 ± 0.14 and 0.36 ± 0.22 relative
densitometric units (RDU), the failing, F + LVAD and F + BF groups, respectively, had
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Figure 54. Binding affinity for muscarinic receptors.
(A) Muscarinic receptor Kd was not significantly different among
groups (p = 0.07). (B) Most patients in the F + BF group had Kd’s
that were at the non-failing level. IP 15 is an outlier.
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Figure 55. SERCA/CALQ.
(A) There were no significant differences in SERCA protein among
groups (p = 0.62). (B) SERCA protein levels in the F + BF group
were variable. OP 2 is an outlier.

117

1.0

0.5

0.0
NF

Failing

F + LVAD

F + BF

1.5

NF
Failing

1.0

0.5

8
11
IP
15
IP
20
IP
21
O
P
2
IP

4

3

6

IP

IP

IP

2

IP

1

0.0
IP

Relative Densitometric Units (RDU)

1.5

IP

B

Relative Densitometric Units (RDU)

A

Figure 56. NCX/CALQ.
(A) There were no significant differences in NCX protein among
groups (p = 0.73). (B) NCX protein levels in the F + BF group were
variable, however most were at or above the non-failing level.
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significantly lower ryanodine receptor (RYR) protein levels than the non-failing group
(0.75 ± 0.26 RDU; overall p < 0.001). Figure 57 highlights these differences and shows
the individual variability in the F + BF group. One F + BF patient had RYR levels at the
non-failing level, and two others were approaching the non-failing average.

3.7 Correlation Data
In order to determine whether patients who were successful with biofeedback
were the same patients who showed changes in the biology of the heart, each
psychophysiologic variable that changed following biofeedback training was correlated
with each changing biological variable. These correlation analyses were performed using
six patients (IP 1, IP 3, IP 4, IP 8, IP 11, IP 15). There were eleven patients in the
biofeedback group on whom biological data were collected (Tables XIV and XV), but
only six of these patients also had before and after biofeedback training data (these six
patients completed all eight sessions of biofeedback) (Table XIII). Linear regression
analyses were also performed, and the results (p-values) are summarized in Table XVII.
No statistically significant relationships were found.
The two correlations highlighted in bold boxes in Table XVII were not significant
(p > 0.05), however both included a point outside the 95% confidence interval. This
point was from the same patient in each relationship, IP 11. Because IP 11 is the only
patient with congenital heart disease in the study, these two relationships were analyzed
both with and without IP 11, and removing this patient created highly significant
relationships between these two sets of variables.
Figure 58 shows the relationship between average respiration rate during the first
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Figure 57. RYR/CALQ.
(A) RYR levels were significantly lower in the failing (p < 0.01), F +
LVAD (p < 0.001) and F + BF (p < 0.001) groups relative to the nonfailing group. (B) RYR protein levels in the F + BF group were
variable, and most were below the failing level. Three patients,
however, showed RYR levels at or approaching the non-failing level.
IP 8 is an outlier.
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Table XVII. Biofeedback vs. Biology Correlation Data
DT
(ISO)

B-AR

MR

RYR

Resp Rate (in Session 8)

0.98

0.71

0.79

0.17

Resp Rate (% Change)

0.17

0.47

0.24

0.85

SDNN (in Session 8)

0.30

0.96

0.30

0.87

SDNN (% Change)

0.45

0.34

0.23

0.37

Agg. CV React (% Change)

0.91

0.61

0.11

0.08

Agg. CV Recover (% Change)

0.22

0.50

0.26

0.72

Homework

0.87

0.16

0.56

0.99

From top to bottom, biofeedback variables analyzed include: Average
respiration rate during the first 5-minute self-relaxation of session 8;
Respiration rate as a percent change from the first 5-minute self-relaxation of
session 1 to the first 5-minute self-relaxation of session 8; Average SDNN
during the first 5-minute self-relaxation of session 8; SDNN as a percent
change from the first 5-minute self-relaxation of session 1 to the first 5-minute
self-relaxation of session 8; Aggregate cardiovascular reactivity as a percent
change difference (session 8 minus session 1); Aggregate cardiovascular
recovery as a percent change difference (session 8 minus session 1);
Number of homework sheets turned in.
DT (ISO) = % change in developed tension following the addition of
isoproterenol; B-AR = Beta-adrenergic receptor density; MR = Muscarinic
receptor density; RYR = Ryanodine receptor protein expression.
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Figure 58. Relationship between respiration rate and ryanodine
receptor protein expression.
(A) WITH IP 11 – There is no significant relationship between
average respiration rate during the first 5-minute self-relaxation of
session 8 and ryanodine receptor protein expression (p = 0.17; R2 =
0.52). (B) WITHOUT IP 11 – Patients who were breathing at lower
rates in session 8 had greater expression of ryanodine receptor protein
(p = 0.02; R2 = 0.97).

122

5-minute self-relaxation of session 8 and expression of the ryanodine receptor protein,
both with and without IP 11. While no significant relationship existed in the presence of
IP 11 (p = 0.17; R2 = 0.52), removing the IP 11 data point created a significant
correlation in which patients who were breathing at lower rates following biofeedback
training had greater expression of ryanodine receptor protein (p = 0.02; R2 = 0.97).
A significant relationship between percent change in respiration rate and
developed tension in response to isoproterenol also emerged when IP 11 was removed, as
shown in Figure 59 (p = 0.01; R2 = 0.90). Specifically, patients who lowered their
respiration the most (negative percent change) had greater developed tension responses to
isoproterenol.
In addition to relationships between biofeedback and biological data, correlations
between transplant wait time following biofeedback training and the biological variables
analyzed above were also explored. Table XVIII displays the number of days patients
waited for transplant following their participation in the biofeedback study, and Table
XVIIII shows the correlation results (p-values). No significant relationships were found.
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Figure 59. Relationship between respiration rate and developed
tension response to isoproterenol.
(A) WITH IP 11 – There is no significant relationship between percent
change in respiration rate and developed tension in response to
isoproterenol (p = 0.17; R2 = 0.41). (B) WITHOUT IP 11 – Patients
who lowered their respiration rate the most had greater developed
tension responses to isoproterenol (p = 0.01; R2 = 0.90).
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Table XVIII. Transplant
Wait Time
Patient ID

BF → TX
(days)

IP1

21

IP 3

37

IP 4

40

IP 8

7

IP 11

257

IP 15

230

125

Table XVIIII. Transplant Wait Time vs. Biology
Correlation Data

BF → Tx (days)

DT (ISO)

B-AR

MR

RYR

0.40

0.65

0.60

0.09

Data are displayed as p-values.
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CHAPTER IV
DISCUSSION

Self-regulation techniques have been explored in the treatment of heart failure
prior to this study.

Mindfulness training has been shown to reduce anxiety and

depression and to improve clinical symptoms in patients with heart failure.106 Quality of
life has been shown to improve following both relaxation training21,124 and meditation26,
and meditation has also been shown to reduce circulating norepinephrine.26

4.1 Biofeedback in End-Stage Heart Failure Patients
Although the potential for other mind-body therapies to play a role in heart failure
has been shown, there have only been a few studies exploring the efficacy of biofeedback
training in patients with documented heart failure, and therefore the ability for heart
failure patients to learn biofeedback was unknown.

Respiration Rate
Respiration rate was the first physiologic modality focused on in the biofeedback-
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assisted stress management training protocol. Patients were taught to breathe from the
diaphragm as opposed to the chest and were encouraged to breathe slowly and deeply.
Over the course of the study, patients were able to progressively decrease their breathing
rate, resulting in a significantly lower rate after only two training sessions. Before
biofeedback training, patients’ average breathing rate was 14.9 ± 2.9 breaths per minute,
and after biofeedback training, average respiration rate decreased to 9.4 ± 2.7 breaths per
minute. This result is similar to a study done by Bernardi and colleagues in 1998,
however that study used diaphragmatic breathing training only, not biofeedback.
Bernardi showed that in nine heart failure patients practicing diaphragmatic
breathing at home for one hour every day for a month, spontaneous breathing rate
dropped from 13.4 ± 1.5 to 7.6 ± 1.9 breaths per minute.7 While the absolute change in
respiration rate is similar in our study and the Bernardi study (~ 5.5 breaths per minute),
patients in the Bernardi study had lower breathing rates both before and after
intervention.

What was not reported in Bernardi’s study, however, are the clinical

demographics of these nine heart failure patients, and it is possible that our heart failure
population (NYHA class III or IV, average LVEF of 23%) had more severe disease.
Other studies exploring the benefits of slower breathing in heart failure patients
did not use biofeedback and did not report respiration rate before and after intervention,
but showed that relative to a control group of heart failure patients, lowering respiration
rate results in decreased dyspnea121, improved exercise tolerance6,121, and lower blood
pressure95.

Digital Peripheral Temperature
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Digital peripheral temperature was measured in this study as an indirect correlate
of peripheral vasoconstriction. When a person is relaxed, their blood vessels dilate,
allowing more warm blood to pass through.

Because biofeedback cannot directly

measure blood vessel diameter, it measures finger temperature instead. This is because
the fingers have a dense network of blood vessels with relatively little surrounding tissue.
As a result, changes in temperature occur relatively more rapidly in the fingertips.103
We expected that biofeedback-assisted stress management training would
augment parasympathetic nervous system activity, causing blood vessels to dilate and
digital peripheral temperature to increase. This is consistent with the findings of Moser
and colleagues in 1997. Moser showed that heart failure patients significantly increased
their finger temperature from 91.5 ± 4.7°F to 94.6 ± 3.1°F after only one session of
biofeedback combined with modified progressive muscle relaxation and imagery of hand
warmth.86
We found that there was essentially no change in finger temperature following
biofeedback training. Patients’ average finger temperature was 89.9 ± 4.1°F before
training and 89.8 ± 5.0°F after training.

What is important to note is that while

participating in this study, patients were still receiving standard medical management for
their heart failure, and except for 3 patients whose medical records were unavailable
(therefore we do not know what medications they were taking), all patients in the study
were on some type of medication with vasodilatory properties. This was not the case in
Moser’s study, as medications were withheld from 12 hours before the study through the
study duration.86
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Heart Rate Variability
Autonomic imbalance is a hallmark of heart failure, reflecting a decreased
resilience in the cardiovascular system to meet the demands of the environment, and is
associated with increased morbidity and mortality.11,60

In recent years, heart rate

variability (HRV) has become a useful tool to measure autonomic balance, and depressed
HRV has been shown to be a marker of poor prognosis in patients with heart failure.90
In this study, heart rate variability was measured by calculating the standard
deviation of the inter-beat intervals (SDNN). This time domain measure is the most
commonly used marker of autonomic function because it reflects all biological
oscillations that lead to variations in heart rate.110

On average, patients’ SDNN

significantly increased following biofeedback training, going from 32 ± 22 msec before
biofeedback training to 44 ± 23 msec after biofeedback training.
The only other study showing the heart failure patients can use biofeedback to
increase HRV came out in 2009 and showed that SDNN increased significantly following
cardiorespiratory biofeedback training but only in patients with ejections fractions equal
to or above 31%.107 Disease severity was greater in our study (average LVEF 23 ± 15%),
and it is now the first to show that end-stage heart failure patients with ejection fractions
at or below 30% can increase their HRV following biofeedback training.
Furthermore, 25% of patients in the current study (5 out of 20) increased their
SDNN from an unhealthy range (0-50 msec) to a moderately healthy range (50-100
msec) as defined by the Task Force of the European Society of Cardiology and the North
American Society of Pacing Electrophysiology.110 Movement into a higher category has
been shown to increase a patient’s probability of survival.
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In 1987, Kleiger and

colleagues found a 4-fold increase in the relative risk of death in 808 patients after
myocardial infarction with low SDNN (≤ 50msec) compared to those with high SDNN (≥
100 msec), and HRV remained the strongest predictor of death after accounting for
demographics, medications, and various clinical factors.60

Psychophysiologic Reactivity and Recovery
In this study, instantaneous heart rate was analyzed before, during and after
mental stress tasks in a psychophysiologic assessment before and after biofeedback
training in an effort to measure both reactivity to and recovery from mental stress.
Studies have shown that stress reactivity is associated with illness severity and is a
predictor of later illness, especially cardiovascular disease.63,114
We expected that patients would react less to psychological stress following
biofeedback training, and that this would be manifest as less of an increase in heart rate
during mental stressors. Several studies have shown that biofeedback training can be
used to control blood pressure during tests of mental stress32,45,64,84, however we did not
measure blood pressure in the current study. Using heart rate to quantify cardiovascular
reactivity, we found no significant change following biofeedback training. We also did
not show an increase in recovery from mental stress following biofeedback training.
Instead no significant differences were found.
There are several limitations to the measurement of cardiovascular reactivity in
the current study.

First, the same stressors were used in the same order in both

psychophysiologic assessments. Patients were informed prior to the last session that the
second psychophysiologic assessment was going to be the same as they experienced in
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the first session. It is difficult to know whether this knowledge would cause patients to
be more relaxed in the second assessment because they know what is coming or if it
could potentially cause patients to be more nervous, anticipating the stressors because
they know what they are.
It is also necessary to consider the effect of the same team (biofeedback
technician and therapist) administering the psychophysiologic assessment in both the first
and last biofeedback sessions. It is possible that patients may have grown comfortable
with the biofeedback team, and again, one could argue that this could make the patient
more calm the second time around or it could add pressure to perform since it is clear to
the patient that they should be less reactive following biofeedback training. Ruminating
about performance in between tasks would certainly keep patients from recovering. One
might also speculate that comfort with the biofeedback team could allow patients to be
more vulnerable over time, actually responding more (reacting more) following
biofeedback training. In this case, patients should still recover more quickly if they were
successful with biofeedback training.

Homework
Patients were provided with relaxation CDs and handheld thermometers and
asked to practice at least 20 minutes each day. Sheets were provided to record daily
stress levels and as well as finger temperature before and after relaxation practice. These
daily record sheets were collected at the beginning of each visit. One limitation to this
approach is that digital peripheral temperature did not significantly change in the office,
and therefore it is unclear if using this modality for home practice actually helped
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patients. One might imagine that it was a source of frustration if patients felt unable to
increase their finger temperature and therefore unable to succeed. On the other hand,
some studies have shown that patients who practice a treatment do so because they find
the treatment to be useful. Overall, 14 out of the 20 patients who finished all eight
sessions of biofeedback (70%) completed some amount of homework.

Subjective Data
Patients were asked to self-report their level of relaxation after every activity
(stressful and relaxing) in each psychophysiologic assessment.

When stressors and

relaxing activities were grouped together, patients reported being more relaxed during
both types of activities after biofeedback training as compared to before training. One
limitation to interpretation of this data is that patients knew they were in a study of
relaxation and stress management, so perhaps they reported what was expected or what
they felt was “the right answer.” Without a validated measure of relaxation and a control
group, there is no way to know if this response would be different in a group of heart
failure patients who did not receive biofeedback-assisted stress management training or
in any cohort based simply on test-retest effects.

Inpatients vs. Outpatients
With respect to respiration rate, inpatients made significant improvement after
two biofeedback training sessions whereas outpatients required four training sessions in
order to significantly lower their breathing rate. This difference may be due to the
frequency with which patients were trained. Inpatients by definition were waiting for a

133

heart transplant in the hospital because they were the sickest of the patients on the
transplant list and therefore the most likely to receive a heart transplant. These patients
were seen more frequently (twice a week for four weeks) in order to have sufficient time
to get through the entire biofeedback-assisted stress management training protocol before
the patients came to transplant. Outpatients were seen once a week for eight weeks, and
so perhaps even if they practiced on their own as encouraged, they would have benefitted
more from more frequent respiratory biofeedback training with a certified psychologist
present.
Across biofeedback sessions, outpatients showed a significant increase in SDNN
that was not present in the inpatient sample. Although not a significant difference, this
may be due to the fact that SDNN before biofeedback training was lower in the outpatient
cohort relative to the inpatients.

Because lower SDNN is a marker of poorer

cardiovascular resilience and prognosis, this does not necessarily support the idea that
inpatients are sicker than outpatients.
The same limitations exist with respect to cardiovascular reactivity and recovery
when analyzed based on patient status, but the fact that inpatients had less time in
between psychophysiologic assessments may have played a role in any differences
between cohorts. Although not statistically significant, there seemed to be an inverse
reactivity relationship between inpatients and outpatients before and after biofeedback
training, wherein inpatients tended to react more following biofeedback training, and
outpatients tended to react less. Perhaps inpatients remembered the stressors more than
outpatients and anticipated them, thereby increasing reactivity.
In addition to the difference in the time course of training between inpatients and

134

outpatients, the treatment setting is also quite different.

One might imagine that

outpatients are living at home waiting for transplant and are therefore dealing with more
real-life stressors than inpatients who are in a controlled hospital environment. As a
result, perhaps they have more practice translating the relaxation and stress management
skills learned in the study to everyday life such that laboratory mental stress tasks were
not as arousing to this cohort after biofeedback-assisted stress management training.
Although they tended to react more, inpatients were shown to recover from mental
stress significantly more than outpatients, and this did not change with biofeedback
training. If taken as a measure of success with biofeedback, then greater cardiovascular
recovery in the inpatient cohort might suggest that the inpatients were more successful
than the outpatients. Again, the analysis of cardiovascular reactivity and recovery is
complex, and it is possible that differences lie solely within the method of measurement
and not a true difference.70
Surprisingly, with respect to the amount of homework completed, outpatients on
average turned in more daily record sheets than inpatients.

Assuming an equal

probability that patients who did their homework would turn it in, this means that
outpatients practiced more than inpatients. Because inpatients were living in the hospital,
often with no visitors other then hospital staff, it was expected that they would practice
more often just due to a lack of other things to do. Perhaps practice in between sessions
was more relevant to this cohort because there was more time in between sessions. Of
course the flaw in this approach is that is doesn’t account for how many homework sheets
each patient could have turned in. Perhaps looking at the percentage of homework turned
in based on the total number of homework sheets the patient could have turned in would
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reflect a different trend. Certainly the length of participation in the study varies between
cohorts (inpatients are in the study for four less weeks), and therefore if an inpatient
turned in the same number of daily record sheets as an outpatient, it would mean that the
inpatient practiced more often.

4.2 The Effect of Biofeedback on Quality of Life
In this study, no significant changes in general or heart failure-specific quality of life
(QOL) were observed following biofeedback training. When separated by patient status,
however, some QOL differences did emerge. Keep in mind that in all cases, higher
scores reflect a greater level of functioning.
On the SF-36, inpatients reported a lower social functioning score than outpatients,
and this did not change with biofeedback. This makes sense because inpatients were
waiting for a heart transplant in the hospital, and therefore probably had fewer
opportunities to socialize than patients waiting for transplantation at home. Inpatients
also reported a greater general health score as compared to outpatients, and this did not
change with biofeedback. This may also be a result of inpatients living in the hospital
because they have access to immediate care whenever they have a question, need a
medication adjusted, etc.
With

respect

to

the

heart

failure-specific

Kansas

City

Cardiomyopathy

Questionnaire, inpatients reported a lower quality of life score than outpatients which did
not change with biofeedback training. Once again, this could be a result of inpatients
living in the hospital while waiting for a heart transplant, perhaps missing the social
connections and freedoms that come with living at home. On the KCCM, the clinical
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summary score is an average of Physical Limitation Score and Total Symptom Score,
reflecting how the patient is feeling physically with his or her heart failure. Inpatients
reported higher clinical summary scores than outpatients, and this did not change with
biofeedback. Again, one might imagine that access to around-the-clock medical care
help inpatients manage the symptoms of heart failure better than outpatients living at
home.
One limitation of the evaluation of quality of life in this study is the lack of an
appropriate control group. We know that these patients’ heart failure is progressing over
time, and one might expect quality of life scores to decline as a result.

Perhaps

biofeedback kept heart failure patients in this study on an even keel such that we are
actually underestimating the effect of biofeedback on quality of life.

4.3 The Effect of Biofeedback on Clinical Course
Clinical data were collected in outpatients only. Inpatients were unable to get out of
bed to do the six minute walk test, and blood could not be drawn for plasma
norepinephrine for logistical reasons.
Plasma norepinephrine was taken as a marker of sympathetic nervous system
activity. High levels of circulating norepinephrine have become a biomarker of heart
failure due to excess sympathetic input, and because we were teaching patients to
decrease sympathetic activity, we expected plasma norepinephrine levels to decrease
after biofeedback training. What we saw was that average plasma norepinephrine levels
did not change following biofeedback training, however plasma norepinephrine did
decrease in three of the eight patients.
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Six-minute walk distance, a common measure of functional capacity in heart
failure patients3, also showed no significant change following biofeedback training. This
finding is consistent with that of Swanson et al. who showed that exercise tolerance did
not improve in patients with a left ventricular ejection fraction ≤ 30%.107 The patients in
the current study who completed the six-minute walk test all had ejection fractions at
30% or below. A study by Luskin in 2002 showed that a combination of biofeedback and
stress management was associated with an increase in exercise tolerance (on average
patients walked 175 feet further after the intervention), however again the patients in that
study had New York Heart Association class I to “very early class III” heart failure, a
population that has less severe disease relative to the patients in the Swanson and current
studies.73
Even though average distance walked did not change with biofeedback training,
the clinical cutoff for improvement or regression in functional capacity is 130 feet3, and
by this criterion, three patients showed clinical improvement in exercise tolerance. These
were not the same three patients who showed decreased levels of circulating
norepinephrine.

4.4 The Effect of Biofeedback on Myocardial Remodeling
In this study, we hypothesized that biofeedback could reverse the heart failure
phenotype. We measured biological changes that we already know occur in heart failure
and recover with LVAD support, including muscle contraction, beta-adrenergic and
muscarinic receptor densities, as well as some of the calcium cycling proteins
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downstream of these receptors. We hypothesized that biofeedback would also show
recovery of such myocardial remodeling.

Muscle Function
Muscle function experiments were conducted in order to measure the response of
individually dissected trabecular muscles to sympathetic nervous system stimulation.
After finding the length at which each muscles produced its greatest contraction (Lmax),
six contractile parameters were analyzed both at baseline as well as after a single dose of
isoproterenol (ISO), a synthetic analogue of norepinephrine. All comparisons were made
relative the non-failing group, and there were no significant differences in any of the six
contractile parameters at baseline. This means that any differences we saw were due to
our experimental manipulation (adding isoproterenol) and not to some initial difference
in muscle function.
For all six contractile parameters, the response to isoproterenol (ISO) was
measured as a percent change from baseline. Because it is known that sympathetic
nervous system activity increases heart rate and force of contraction, we expected to see
the following changes in the non-failing (NF) group: (1) Resting tension (RT) is the
amount of tension a muscle generates at rest and was expected to decrease, (2) Developed
tension (DT) is the amount of force a muscle generates during contraction and was
expected in increase, (3) Time to peak tension (TPT) is the amount of time it takes for a
muscle to reach the peak of contraction once it begins to contract and was expected to
decrease, (4) Time to half relaxation (THR) is the amount of time it takes for a muscle to
get from the peak of contraction to the halfway point of relaxation and was expected to
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decrease, (5) Peak rate of tension rise (+dT/dt) is the point at which the muscle is
contracting the fastest and was expected to increase, and (6) Peak rate of tension fall (dT/dt) is the point at which the muscle is relaxing the fastest and was expected to
increase. We know that these effects are depressed in muscles from patients with heart
failure and to recover in muscles from patients with LVAD support. We hypothesized
that the magnitude of the outlined changes will not be significantly different between the
non-failing and failing + biofeedback (F + BF) groups.
The RT response to ISO decreased as expected with no significant differences
among groups. Statistical significance was almost reached, however, and with mean
values of -11.1 ± 6.0% and -10.6 ± 3.2%, the failing and F + LVAD groups showed less
of a decrease in resting tension relative to the NF and F + BF groups (-16.1 ± 8.8% and 15.3 ± 2.9, respectively).
The DT response to ISO increased across all four groups, however muscles taken
from failing hearts contracted significantly less than muscles taken from non-failing
hearts. These results were as expected. In support of our hypothesis, there was no
significant difference in DT response to ISO between the NF and F + BF groups,
suggesting that biofeedback is associated with recovery of the functional response to ISO
in individual cardiac muscles. On an individual patient basis, muscles taken from eight
patients in the F + BF group contracted more than the average failing level, with muscles
from three of these patients contracting at or above the non-failing level.
As expected, TPT and THR both decreased in response to ISO. No significant
differences were found among groups with respect to either contractile parameter.
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In order for heart rate to increase, the rate of contraction and relaxation must
increase, and these results were shown in the peak rate of tension rise and fall responses
to ISO across all four groups. As expected, the +dT/dt and -dT/dt responses were
significantly lower in the failing group and recovered in the F + LVAD group. Although
not to the same degree as the LVAD group, muscles in the F + BF group were not
significantly different from muscles in the non-failing group with respect to +dT/dt or dT/dt. For the three patients in the F + BF group whose developed tension response to
ISO was at or above non-failing levels, the same was true of their +dT/dt and -dT/dt
responses.

Beta-Adrenergic Receptors
Several studies have shown that beta-adrenergic receptor density is decreased in
human heart failure, and that this reduction is reversed with LVAD support. In 2001,
DiPaola and colleagues showed a 53% decrease in beta receptor density in failing human
hearts relative to non-failing human hearts.27 This confirmed the much earlier landmark
study by Bristow and colleagues which also showed that there about 50% less beta
receptors in failing human hearts than there are in non-failing human hearts.19 OgletreeHughes et al. showed that beta-adrenergic receptor density in hearts with LVAD support
was comparable to that in non-failing hearts.92
In the current study, we expected to replicate these results, showing a decrease in
beta-adrenergic receptor density that is reversed in heart failure patients with an LVAD,
and we hypothesized that the F + BF group would also show a recovery of beta-
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adrenergic receptors, especially since we saw recovery in the functional response
(developed tension response to ISO).
Although the magnitude of change was less (32%) than in previous studies (50%
and 53%), we saw a significant decrease in beta-adrenergic receptor density in failing
human hearts relative to non-failing hearts. We showed no significant difference in betareceptor density between the non-failing and F + LVAD groups, confirming the recovery
of LVAD-supported failing hearts shown in other studies. Beta receptor density in the F
+ BF group was significantly lower than that of the non-failing group, suggesting that
biofeedback is not associated with the recovery of beta-adrenergic receptor density.
On an individual basis, three patients in the F + BF group did show recovery of
beta-adrenergic receptors such that they were at or even above the non-failing average.
Only one of these patients was one who also exhibited a developed tension response to
isoproterenol at the non-failing level.
One can speculate that increased levels of circulating norepinephrine in heart
failure patients may play a role in decrease in beta-adrenergic receptor density. If all of
the excess NE were to bind the beta-receptors, the subsequent response would use up a
ton of cellular ATP. Studies have shown normalization of plasma norepinephrine in
LVAD patients, and so perhaps this is responsible for beta-adrenergic receptor recovery.
This might also be a potential mechanism of action for biofeedback considering that
some patients did exhibit beta receptor recovery.

These patients were inpatients,

however, and therefore plasma norepinephrine was not collected. In order to answer this
mechanistic question, one would have to show a relationship between normalized
(increased) beta receptor density and decreased plasma norepinephrine levels following
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biofeedback training.
In receptor binding studies, the relationship between the rate of formation and
dissociation of the ligand-receptor complex is called the equilibrium dissociation constant
(Kd). Kd is the reciprocal of the affinity of a ligand for a receptor, and so Kd was
measured across groups in this study as an inverse measure of binding affinity. This
means that lower Kd values for a particular receptor indicate a higher binding affinity of
the ligand for the receptor. One might imagine that functional changes can be due to an
increased number of the receptor mediating the response or to an increased affinity of
ligand for the receptor.
Results show no significant changes in beta-adrenergic receptor Kd across groups.
In the F + BF group, however, half of the patients exhibited a much higher Kd than the
other half of patients.

Muscarinic Receptors
Muscarinic receptor expression in the human heart is not nearly as wellcharacterized (in health or disease) as is the expression of beta-adrenergic receptors.
Early studies of muscarinic receptor density in humans showed no significant differences
in muscarinic receptor density between failing and non-failing hearts. In 1990, Bohm et
al. measured muscarinic receptor density in 16 failing and 5 non-failing human hearts
using radioligand binding with a tritiated antagonist and showed that although there were
less receptors in failing hearts (211 ± 22 fmol/mg protein vs. 275 ± 21 fmol/mg protein in
non-failing hearts) the difference was not statistically significant.15 The opposite result
was shown by Le Guludec and colleagues who used positron emission tomography (PET)

143

to non-invasively measure myocardial muscarinic receptors in 20 heart failure patients
and 12 normal controls. This study showed that average muscarinic receptor density was
significantly higher in the patients with heart failure relative to controls (34.5 ± 8.9
pmol/mL and 25.0 ± 7.8 pmol/mL, respectively).65
In the current study, we showed that muscarinic receptor density was significantly
greater in failing human hearts relative to non-failing hearts (166.1 ± 45.9 fmol/mg
protein vs. 92.1 ± 25.2 fmol/mg protein). LVAD-supported hearts exhibited even more
muscarinic receptors, with a density of 221.1 ± 61.3 fmol/mg protein.

Muscarinic

receptor density in the F + BF group (123.2 ± 26.4 fmol/mg protein) was not significantly
different from that of the non-failing group.
The only other study to measure muscarinic receptor density in heart failure
patients with an LVAD came out of the Moravec laboratory last year, and it confirmed
the results of the current study, showing a similar increasing relationship in muscarinic
receptor density across non-failing, failing and LVAD-supported hearts.42
One might speculate that muscarinic receptors are up-regulated in failing hearts in
an attempt to combat sympathetic nervous system (SNS) hyperactivity by increasing
parasympathetic nervous system input to the cardiovascular system. Because the LVAD
has been shown to reverse remodel the cellular and molecular changes associated with
SNS hyperarousal, it would make sense to think that the need for elevated muscarinic
receptors would go away, and there would be a normalization of muscarinic receptor
density in LVAD-supported hearts. Instead, muscarinic receptor density was shown to
further increase in the F + LVAD group. This may suggest that parasympathetic nervous
system hypoactivation does not recover in patients with heart failure supported by an
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LVAD. Because no significant difference was found in muscarinic receptor density
between the non-failing and F + BF groups, this might also suggest that biofeedback is
associated with a normalization of muscarinic receptors in patients with end-stage heart
failure.
When the muscarinic receptor Kd was analyzed across groups, the F + LVAD
group was significantly higher than the non-failing group. This means that binding
affinity for muscarinic receptors is lower in LVAD-supported hearts. As previously
discussed, the density of muscarinic receptors increased in this group. What is unknown
is the temporal relationship between receptor density and receptor affinity. Perhaps
muscarinic receptor density increased and then affinity decreased to compensate for an
increase in signal transmission. Or maybe binding affinity for muscarinic receptors
decreased and then receptor density increased in an attempt to restore the signal.
It is also possible that the differences in muscarinic receptor Kd are due to a
difference in the distribution of muscarinic receptor subtypes, and it would be interesting
to measure these subtypes across all four groups of patients going forward. While the
exact reason for the difference in Kd in the F + LVAD group is unclear, our group of
interest, the F + BF group, did not show a significant difference in muscarinic receptor
binding affinity relative to non-failing hearts.

Calcium Cycling Proteins
With the exception of the ryanodine receptor, calcium cycling proteins were
chosen because the changes in heart failure and heart failure with LVAD support were
well-documented and well-understood. Specifically, SERCA is decreased and NCX is
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increased in failing human hearts, leading to decreased contractile function.

These

changes in calcium cycling proteins are reversed and contractile function is improved in
LVAD-supported hearts.28 We expected to replicate these results in the current study,
and we hypothesized that hearts in the F + BF group would exhibit reverse remodeling of
calcium cycling proteins like what has been shown with LVAD support. In all cases,
calsequestrin was used to normalize the data because protein levels have consistently
been shown not to change in heart failure.27,53,83
Both SERCA/CALQ and NCX/CALQ protein levels showed no differences
among groups in this study. The expected changes in failing and LVAD-supported hearts
were not replicated, making comparisons between the non-failing group and F + BF
group difficult to interpret.

In a way, the lack of significant differences in

SERCA/CALQ and NCX/CALQ protein levels between non-failing and F + BF hearts
supports our hypothesis, however after consideration of the possible reasons why the
expected changes were not replicated, it is unlikely that such a suggestion can be made.
What has been noticed in our laboratory is that calcium cycling protein
measurements are variable based on the patient sample selected. Sometimes a group of
patients exhibits the expected differences are shown, and sometimes they do not. This is
worth exploring further since many gene therapy trials have begun to alter levels of
calcium cycling proteins based on these “known changes” that we no longer see
consistently in the laboratory.
The calcium cycling protein that did show changes across groups in this study
was the ryanodine receptor. RYR/CALQ levels decreased significantly in the failing
group relative to the non-failing group, and a further decrease was shown in the F +
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LVAD and F + BF groups. Because there is no consensus in the literature with respect to
RYR protein expression51, the results of the current study are open to interpretation. If
RYR protein levels are depressed in heart failure, this would mean less calcium would be
released from the sarcoplasmic reticulum and into the cytosol to bind the myofilaments
and cause cardiomyocyte contraction. The fact that RYR/CALQ levels do not recover in
LVAD-supported hearts is counterintuitive, as one might imagine RYR receptors would
be normalized in this group in order to improve muscle contractility.
Combined with the absence of changes in SERCA/CALQ and NCX/CALQ
protein levels, a decrease in RYR/CALQ level does not support the normalization of
contractile function that was shown in the F + BF group. Because it is a calcium release
channel, decreased RYR protein would keep calcium from being released from the
sarcoplasmic reticulum (SR). Without being released into the cytosol where it can bind
to myofilaments and enhance myocardial contractility, calcium is of no use in the SR.
Perhaps calcium is released through the IP3 receptor which means that activation of the
odd-numbered muscarinic receptors would be necessary. Without measuring muscarinic
receptor subtypes, one can only speculate that the odd-numbered receptors play a greater
role in releasing calcium into the cytosol and thereby improving contractile function in
the F + BF group. The only other study that measured muscarinic receptor density in
non-failing, failing and LVAD-supported hearts also measured muscarinic receptor
subtypes and showed that the percentage of odd-numbered muscarinic receptors goes up
in the F + LVAD group42, supporting this idea as a possible mechanism in the current
study for the F + BF group.
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4.5 Correlation Data
In an attempt to determine whether patients who were successful with biofeedback
were the same patients who showed biological changes in the heart, each biofeedback
variable that changed was correlated with the four biological variables that changed or
were variable including the developed tension response to ISO, beta-adrenergic receptor
density, muscarinic receptor density, and RYR/CALQ protein concentration.
Although no significant relationships were found, two correlations included a data
point that was outside the 95% confidence interval. This point was found to be from the
same patient in both data sets, the only patient with congenital heart failure in this patient
cohort. Because the mechanism of congenital heart failure may be different from dilated
and ischemic cardiomyopathies, this point was removed from both data sets, and
significant relationships emerged.
Patients who were breathing at slower rates in session eight of the biofeedbackassisted stress management training protocol showed greater expression of RYR protein
levels. Even though overall RYR protein expression was lower in the F + BF group
relative to the non-failing group, this suggests that success with respiration training may
help to normalize RYR protein level.
The second significant correlation that emerged showed that patients who showed a
greater percent decrease in respiration rate also showed the greatest developed tension
response to isoproterenol. This suggests that breathing at lower rates may decrease
background sympathetic nervous system arousal such that the cardiovascular system can
respond to increases in sympathetic activity (demand).
The numbers of days patients waited between their last session of the biofeedback-
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assisted stress management training protocol and their date of heart transplantation was
also correlated with the four biological variables listed above, and no significant
relationships were found.

4.6 Summary
With improvements like a decrease in respiration rate and an increase in heart rate
variability, end-stage heart failure patients in this study were certainly able to use
biofeedback to learn how to modify certain physiologic variables. Although no control
group was included for comparison, it is possible that biofeedback-assisted stress
management training may have improved quality of life and clinical course in some
patients in the cohort. Many patients asked to continue receiving biofeedback after their
participation in the study had ended, and sometimes cardiologists requested that we enroll
one of their patients in the study because they felt it would be beneficial to them. One
patient’s medical chart documents her comments specifically regarding participation in
this biofeedback study. She says, “I thought it was helpful. When going into an anxiety
state, I can get into a calm place. It helps with negative thoughts.” When asked whether
or not biofeedback has lost its effectiveness five months after the study, she said no.
On the biological side, contractile response to beta-adrenergic stimulation recovered
in some patients, and other patients showed recovery in beta-adrenergic receptor density.
Because the expected results with respect to calcium cycling proteins were not exhibited,
it is unclear what the lack of differences between SERCA and NCX expression in NF and
F + BF hearts actually means. RYR protein expression was shown to be decreased in the
F + BF group which may have something to do with the recovery of muscarinic receptor
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density also shown in this group, however further studies must be done in order to
explore the mechanisms involved in the biological changes shown in this study.

4.7 Future Directions
One question that was left unanswered in this study is whether or not patients
incorporated the relaxation and stress management skills into their daily lives. It is
possible that patients were able to control their physiology when prompted to do so
during biofeedback training, and a follow-up measurement at some later date after the
conclusion of the study would provide some insight into the endurance of biofeedbackassisted stress management training.
Considering the recent work by Kevin Tracey that showed decreased vagal control of
the heart can have pro-inflammatory consequences that exacerbate the heart failure
condition57,113, it might also be interesting to measure pro-inflammatory cytokines before
and after biofeedback training. Other questions one could ask are (1) Does biofeedback
decrease transplant recovery time? or (2) Does biofeedback decrease transplant rejection?
In order to measure parasympathetic nervous system activity to correlate with these
endpoints would be to use frequency domain analyses of heart rate variability.
Over the course of this study, it has become clear that the end-stage heart failure
population is very challenging to study, and it would be interesting to see if biofeedbackassisted stress management training can be effective in patients with earlier stages of
cardiovascular disease. Gender and diagnosis-specific differences may also be worth
exploring in the future as the potential for biofeedback-assisted stress management
training to change cardiovascular biology continues to grow.

150

REFERENCES

1.

AHA Statistical Update 2012: Heart Disease and Stroke Statistics. Circulation
2012; 125:e2-e220.

2.

Altemose GT, Gritsus V, Jeevanandam V, Goldman B, Marguiles KB. Altered
myocardial phenotype after mechanical support in human beings with advanced
cardiomyopathy. J Heart Lung Transplant 1997; 16:765-773.

3.

American Thoracic Society. ATS statement: guidelines for the six-minute walk
test. Am J Respir Crit Care Med 2002; 166:111-117.

4.

Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in
cardiac hypertrophy and heart failure. Circ Res 1994; 74:555-564.

5.

Barbone A, Holmes JW, Heerdt PM, The’ AHS, Naka Y, Joshi N, Daines M,
Marks AR, Oz MC, Burkhoff D. Comparison of right and left ventricular
responses to left ventricular assist device support in patients with severe heart
failure. Circulation 2001; 104:670-675.

6.

Bernardi L, Porta C, Spicuzza L, Bellwon J, Spadacini G, Frey AW, et al. Slow
breathing increases arterial baroreflex sensitivity in patients with chronic heart
failure. Circulation 2002; 105:143-145.

7.

Bernardi L, Spadacini G, Bellwon J, Hajric R, Roskamm H, Frey AW. Effect of
breathing rate on oxygen saturation and exercise performance in chronic heart
failure. Lancet 1998; 351:1308-1311.

8.

Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 425:198-205.

151

9.

Bers DM. Excitation-contraction coupling and cardiac contractile force. Kluwer
Academic Publishers: Dordrecht, 1993.

10.

Bers DM, Pogwizd SM, Schlotthauer K. Upregulated Na/Ca exchange is
involved in both contractile dysfunction and arrhythmogenesis in heart failure.
Basic Res Cardiol 2002; 97:(Suppl 1):I36-I42.

11.

Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several shortterm measures of RR variability to predict mortality after myocardial infarction.
Circulation 1993; 88:927-934.

12.

Binder T, Frey B, Porenta G, Heinz G, Wutte M, Kreiner G, et al. Prognostic
value of heart rate variability in patients awaiting cardiac transplantation.
Pacing Clin Electrophysiol 1992; 15:2215-2220.

13.

Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. Parasympathetic
withdrawal is an integral component of autonomic imbalance in congestive
heart failure: demonstration in human subjects and verification in a paced
canine model of ventricular failure. J Am Coll Cardiol 1991; 18:464-472.

14.

Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ. Differential gene
expression and genomic patient stratification following left ventricular assist
device support. J Am Coll Cardiol 2003; 41:1096-1106.

15.

Bohm M, Ungerer M, Erdmann E. Beta adrenoceptors and m-cholinoceptors in
myocardium of hearts with coronary artery disease of idiopathic dilated
cardiomyopathy removed at cardiac transplantation. Am J Cardiol 1990;
66:880-882.

152

16.

Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress.
Circulation 2000; 102:(Suppl IV):IV14-IV23.

17.

Bristow MR. β-Adrenergic receptor blockade in chronic heart failure.
Circulation 2000; 101:558-569.

18.

Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am
J Cardiol 1997; 80:26L-40L.

19.

Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K,
et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density
in failing human hearts. N Engl J Med 1982; 307:205-211.

20.

Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human
heart. Pharmacol Rev 1999; 51:651-690.

21.

Chang BH, Hendricks A, Zhao Y, Rothendler JA, LoCastro JS, Slawsky MT. A
relaxation response randomized trial on patients with chronic heart failure. J
Cardiopulm Rehab 2005; 25:149-157.

22.

Cohn JN. Plasma norepinephrine and mortality. Clin Cardiol 1995; 18:(Suppl
I):I9-I12.

23.

Cohn JN. Structural basis for heart failure: ventricular remodeling and its
pharmacological inhibition. Circulation 1995; 91:2504-2507.

24.

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical
implications: a consensus paper from an International Forum on Cardiac
Remodeling. J Am Coll Cardiol 2000; 35:569-582.

153

25.

Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma
norepinephrine as a guide to prognosis in patients with chronic heart failure. N
Engl J Med 1984; 311:819-823.

26.

Curiati JA, Bocchi E, Freire JO, Arantes AC, Braga M, Garcia Y, et al.
Meditation reduces sympathetic activation and improves quality of life in
elderly patients with optimally treated heart failure: a prospective randomized
study. J Altern Complement Med 2005; 11:465-472.

27.

DiPaola NR, Sweet WE, Stull LB, Francis GS, Moravec CS. Beta-adrenergic
receptors and calcium cycling proteins in normal, hypertrophied and failing
human hearts: transition from hypertrophy to failure. J Mol Cell Cardiol 2001;
33:1283-1295.

28.

Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Marguiles KB. Myocyte
recovery after mechanical circulatory support in humans with end-stage heart
failure. Circulation 1998; 97:2316-2322.

29.

Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic
control in patients with heart disease. N Engl J Med 1971; 285:877-883.

30.

Esler M. Pathophysiology of the human sympathetic nervous system in
cardiovascular diseases: the transition from mechanisms to medical
management. J Appl Physiol 2010; 108:227-237.

31.

Felder CC. Muscarinic acetylcholine receptors: signal transduction through
multiple effectors. FASEB J 1995; 9:619-625.

154

32.

Fey SG, Lindholm E. Systolic blood pressure and heart rate changes during
three sessions involving biofeedback or no feedback. Psychophysiology 1975;
12:513-519.

33.

Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin
binding protein C: its role in physiology and disease. Circ Res 2004; 94:12791289.

34.

Flesch M, Marguiles KB, Mochmann HC, Engel D, Sivasubramanian N, Mann
DL. Differential regulation of mitogen-activated protein kinases in the failing
human heart in response to mechanical unloading. Circulation 2001; 104:22732276.

35.

Flesch M, Schwinger RH, Schiffer F, Frank K, Sudkamp M, Kuhn-Regnier F,
et al. Evidence for functional relevance of an enhanced expression of the Na+Ca2+ exchanger in failing human myocardium. Circulation 1996; 94:992-1002.

36.

Flesch M, Schwinger RH, Schnabel P, Schiffer F, Van Gelder I, Bavendiek U,
et al. Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and
protein levels in end-stage heart failure due to ischemic or dilated
cardiomyopathy. J Mol Med 1996; 74:321-332.

37.

Floras JS. Sympathetic nervous system activation in human heart failure:
clinical implications of an updated model. J Am Coll Cardiol 2009; 54:375-385.

38.

Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of
the β-adrenergic receptor pathway in the intact failing human heart: progressive
receptor down-regulation and subsensitivity to agonist response. Circulation
1986; 74:1290-1302.

155

39.

Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al.
Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50:823830.

40.

Francis GS, Cohn JN, Johnson G, Rector JS, Goldman S, Simon A. Plasma
norepinephrine, plasma renin activity, and congestive heart failure: relations to
survival and the effects of therapy in V-HeFT II. Circulation 1993; 87:(Suppl
VI):VI40-VI48.

41.

Frazier OH, Benedict CR, Radovancevic B, Bick RJ, Capek P, Springer WE, et
al. Improved left ventricular function after chronic left ventricular unloading.
Ann Thorac Surg 1996; 62:675-682.

42.

French JA. The parasympathetic nervous system in human heart failure. MS
Thesis 2011: Cleveland State University.

43.

Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of
cardiac myocytes in heart failure. J Mol Cell Cardiol 1995; 27:849-856.

44.

Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N
Engl J Med 1998; 339:1522-1533.

45.

Goodie JL, Larkin KT. Changes in hemodynamic response to mental stress with
heart rate feedback training. Appl Psychophysiol Biofeedback 2001; 26:293309.

46.

Grabellus F, Levkau B, Sokoll A, Welp H, Schmid C, Deng MC, Takeda A,
Breithardt G, Baba HA. Reversible activation of nuclear factor-κB in human
end-stage heart failure after left ventricular mechanical support. Cardiovasc Res
2002; 53:124-130.

156

47.

Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation
of the Kansas City Cardiomyopathy Questionnaire: a new health status measure
for heart failure. J Am Coll Cardiol 2000; 35:1245-1255.

48.

Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman
W, et al. Abnormal intracellular calcium handling in myocardium from patients
with end-stage heart failure, Circ Res 1987; 61:70-76.

49.

Hadri L, Hajjar RJ. Calcium cycling proteins and their association with heart
failure. Clin Pharmacol Ther 2011; 90:620-624.

50.

Hall JL, Fermin DR, Birks EJ, Barton PJR, Slaughter M, Eckman P, et al.
Clinical, molecular, and genomic changes in response to a left ventricular assist
device. J Am Coll Cardiol 2011; 57:641-652.

51.

Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure.
Cardiovasc Res 1998; 37:279-289.

52.

Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske P, Holtz J, et al. Relation
between myocardial function and expression of sarcoplasmic reticulum Ca(2+)ATPase in failing and nonfailing human myocardium. Circ Res 1994; 75:434442.

53.

Hasenfuss G, Reinecke H, Studer R, Pieske B, Meyer M, Drexler H, et al.
Calcium cycling proteins and force-frequency relationship in heart failure.
Basic Res Cardiol 1996; 91:(Suppl 2):17-22.

54.

Hasenfuss G, Schillinger W, Lehnart SE, Preuss M, Pieske B, Maier LS, et al.
Relationship between Na+-Ca2+-exchanger protein levels and diastolic function
of failing human myocardium. Circulation 1999; 99:641-648.

157

55.

Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz
MC, Marks AR, Burkhoff D. Chronic unloading by left ventricular assist device
reverses contractile dysfunction and alters gene expression in end-stage heart
failure. Circulation 2000; 102:2713-2719.

56.

Hon EH, Lee ST. Electronic evaluation of the fetal heart rate patterns preceding
fetal death. Am J Obsted Gynecol 1965; 87:814-826.

57.

Huston JM, Tracey KJ. The pulse of inflammation: heart rate variability, the
cholinergic anti-inflammatory pathway and implications for therapy. J Intern
Med 2011; 269:45-53.

58.

James KB, McCarthy PM, Thomas JD, Vargo R, Hobbs RE, Sapp S, Bravo E.
Effect of the implantable left ventricular assist device on neuroendocrine
activation in heart failure. Circulation 1995; 92 (suppl II): II191-195.

59.

Kaye DM, Lefkovtis J, Jennings GL, Bergin P, Broughton A, Murray DE.
Adverse consequences of high sympathetic nervous activity in the failing
human heart. J Am Coll Cardiol 1995; 26:1257-1263.

60.

Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and
its association with increased mortality after acute myocardial infarction. Am J
Cardiol 1987; 59:256-262.

61.

La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, et al.
Short-term heart rate variability strongly predicts sudden cardiac death in
chronic heart failure patients. Circulation 2003; 107:565-570.

62.

Lamba S, Abraham WT. Alterations in adrenergic receptor signaling in heart
failure. Heart Fail Rev 2000; 5:7-16.

158

63.

Larkin, KT. Stress and hypertension: examining the relation between
psychological stress and high blood pressure. New Haven: Yale University
Press; 2005.

64.

Larkin KT, Zayfert C, Abel JL, Veltum LG. Reducing heart rate reactivity to
stress with feedback. Behav Modif 1992; 16:118-131.

65.

Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P.
Increased myocardial muscarinic receptor density in idiopathic dilated
cardiomyopathy. Circulation 1997; 96:3416-3422.

66.

Lehrer PM, Woolfolk RL, Sime WE. Principles and practice of stress
management, 3rd ed. New York: Guilford Press; 2007.

67.

Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D. Reversal of
chronic ventricular dilation in patients with end-stage cardiomyopathy by
prolonged mechanical unloading. Circulation 1995; 91:2717-2720.

68.

Levy MN. Brief reviews: sympathetic-parasympathetic interactions in the heart.
Circ Res 1971; 29:437-445.

69.

Levy MN, Zieske H. Autonomic control of cardiac pacemaker activity in
atrioventricular transmission. J Appl Physiol 1969; 27:465-470.

70.

Linden W, Earle TL, Gerin W, Christenfeld N. Physiological stress reactivity
and recovery: conceptual siblings separated at birth? J Psychosom Res 1997;
42:117-135.

71.

Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic
signaling in heart failure? Circ Res 2003; 93:896-906.

159

72.

Lowes BD, Minobe WA, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA,
et al. Changes in gene expression in the intact human heart: downregulation of
alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J
Clin Invest 1997; 100:2315-2324.

73.

Luskin F, Reitz M, Newell K, Quinn TG, Haskell W. A controlled pilot study
of stress management training of elderly patients with congestive heart failure.
Prev Cardiol 2002; 5:168-172.

74.

MacLeod CM. Half a century of research on the Stroop effect: an integrative
review. Psychol Bull 1991; 109:163-203.

75.

Mann DL. Mechanisms and models in heart failure: a combinatorial approach.
Circulation 1999; 100:999-1008.

76.

Mann DL, Young JB. Basic mechanisms in congestive heart failure:
recognizing the role of pro-inflammatory cytokines. Chest 1994; 105:897-904.

77.

Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et
al. PKA phosphorylation dissociates FKBP12.6 from the calcium release
channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000;
101:365-376.

78.

McCarthy PM, Savage RM, Fraser CD, Vargo R, James KB, Goormastic MPH,
et al. Hemodynamics and physiologic changes during support with an
implantable left ventricular assist device. J Thorac Cardiovasc Surg 1995;
109:409-418.

160

79.

McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item ShortForm Health Survey (SF-36): III. Tests of data quality, scaling assumptions,
and reliability across diverse patient groups. Med Care 1994; 32:40-66.

80.

McHorney CA, Ware JE, Raczek AE. The MOS 36-item Short-Form Health
Survey (SF-36): II. Psychometric and clinical tests of validity in measuring
physical and mental health constructs. Med Care 1993; 31:247-263.

81.

McKee MG. Biofeedback: an overview in the context of heart-brain medicine.
Cleve Clin J Med 2008; 75: (Suppl 2): S31-S34.

82.

Mercadier JJ, Lompre AM, Duc P, Boheler KR, Fraysse JB, Wisnewsky C, et
al. Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the
human ventricle during end-stage heart failure. J Clin Invest 1990; 85:305-309.

83.

Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, et
al. Alterations of sarcoplasmic reticulum proteins in failing human dilated
cardiomyopathy. Circulation 1995; 92:778-784.

84.

Miller NE. Biofeedback and visceral learning. Ann Rev Psychol 1978; 29:373404.

85.

Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform
expression in the failing and nonfailing human heart. Circ Res 2000; 86:386390.

86.

Moser DK, Dracup K, Woo MA, Stevenson LW. Voluntary control of vascular
tone by using skin-temperature biofeedback-relaxation in patients with
advanced heart failure. Altern Ther Health Med 1997; 3:51-59.

161

87.

Moss D, McGrady A, Davies TC, Wickramasekera I. Handbook of mind-body
medicine for primary care. London: Sage Publications; 2003.

88.

Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy
chain gene expression in human heart failure. J Clin Invest 1997; 100:23622370.

89.

Nakatani S, McCarthy PM, Kottke-Marchant K, Harasaki H, James KB, Savage
RM, et al. Left ventricular echocardiographic and histologic changes: impact of
chronic unloading by an implantable ventricular assist device. J Am Coll
Cardiol 1996; 27:894-901.

90.

Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al.
Prospective study of heart rate variability and mortality in chronic heart failure:
results of the United Kingdom Heart Failure Evaluation and Assessment of
Risk Trial (UK-Heart). Circulation 1998; 98:1510-1516.

91.

O’Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and
responsiveness of quality of life assessment and six minute walk test in elderly
heart failure patients. Heart 1998; 80:377-382.

92.

Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM,
Moravec CS. Mechanical unloading restores beta adrenergic responsiveness
and reverses receptor downregulation in the failing human heart. Circulation
2001; 104:881-886.

93.

Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous
system and heart failure: pathophysiology and potential implications for
therapy. Circulation 2008; 118:863-871.

162

94.

Organ Procurement and Transplantation Network (OPTN) and Scientific
Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data
Report. Rockville, MD: Department of Health and Human Services, Health
Resources and Services Administration, Healthcare Systems Bureau, Division
of Transplantation; 2011:89.

95.

Parati G, Malfatto G, Boarin S, Branzi G, Caldara G, Giglio A, et al. Deviceguided paced breathing in the home setting: effects on exercise capacity,
pulmonary and ventricular function in patients with chronic heart failure: a pilot
study. Circ Heart Fail 2008; 1:178-183.

96.

Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JF, et al.
Autonomic pathophysiology in heart failure patients: sympathetic-cholinergic
interrelations. J Clin Invest 1990; 85:1362-1371.

97.

Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL,
Moravec CS, Davies PJA, Frazier OH, Taegtmeyer H. Downregulation of
metabolic gene expression in failing human heart before and after mechanical
unloading. Cardiology 2002; 97:203-209.

98.

Reinecke H, Studer R, Vetter R, Holtz I, Drexler H. Cardiac Na+/Ca2+ exchange
activity in patients with end-stage heart failure. Cardiovasc Res 1996; 31:48-54.

99.

Reiser PJ, Portman MA, Ning XH, Moravec CS. Human cardiac myosin heavy
chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol Heart
Circ Physiol 2001; 280:H1814-H1820.

163

100. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky
W, et al. Long-term use of a left ventricular assist device for end-stage heart
failure. N Engl J Med 2001; 345:1435-1443.
101. Savinova OV, Gerdes AM. Myocyte changes in heart failure. Heart Fail Clin
2012; 8:1-6.
102. Schneider L. Serial Sevens Test. Arch Intern Med 1983; 143:612.
103. Schwartz MS, Andrasik F. Biofeedback: a practitioner’s guide. 3rd ed. New
York: Guilford Press; 2003.
104. Studer R, Reinecke H, Bilger J, Eschenhagen T, Bohm M, Hasenfuss G, et al.
Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human
heart failure. Circ Res 1994; 75:443-453.
105. Sulakhe PV, Vo XT. Regulation of phospholamban and troponin-I
phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic
stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases
and depolarization. Mol Cell Biochem 1995; 149:103-126.
106. Sullivan MJ, Wood L, Terry J, Brantley J, Charles A, McGee V, et al. The
support, education, and research in chronic heart failure study (SEARCH): a
mindfulness-based psychoeducational intervention improves depression and
clinical symptoms in patients with chronic heart failure. Am Heart J 2009;
157:84-90.
107. Swanson KS, Gevirtz RN, Brown M, Spira J, Guarneri E, Stoletniy L. The
effect of biofeedback on function in patients with heart failure. Appl
Psychophysiol Biofeedback 2009; 34:71-91.

164

108. Takahashi T, Allen PD, Lacro RV, Marks AR, Dennis AR, Schoen FJ, et al.
Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes
in the myocardium of patients with end-stage heart failure. J Clin Invest 1992;
90:927-935.
109. Tang WHW, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, et al.
National academy of clinical biochemistry laboratory medicine practice
guidelines: clinical utilization of cardiac biomarker testing in heart failure.
Circulation 2007; 116:e99-e109.
110. Task Force of the European Society of Cardiology and the North American
Society of Pacing and Electrophysiology. Heart rate variability: standards of
measurement, physiological interpretation, and clinical use. Circulation 1996;
93:1043-1065.
111. Thompson LO, Skrabal CA, Loebe M, Lafuente JA, Roberts RR, Akgul A,
Jones V, Bruckner BA, Thohan V, Noon GP, Youker KA. Plasma
neurohormone

levels

correlate

with

left

ventricular

functional

and

morphological improvement in LVAD patients. J Surg Res 2005; 123:25-32.
112. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al.
Tumor necrosis factor alpha and tumor necrosis factor receptors in the failing
human heart. Circulation 1996; 93:704-711.
113. Tracey KJ. The inflammatory reflex. Nature 2002; 420:853-859.
114. Treiber FA, Kamarck T, Schneiderman N, Sheffield D, Kapuku G, Taylor T.
Cardiovascular reactivity and development of preclinical and clinical disease
states. Psychosom Med 2003; 65:46-62.

165

115. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler
J.

The

sympathetic

nervous

system

in

heart

failure:

physiology,

pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54:17471762.
116. Tsuji H, Venditti FJ, Manders ES, Evans JC, Larson MG, Feldman CL, et al.
Reduced heart rate variability and mortality risk in an elderly cohort: the
Framingham Heart Study. Circulation 1994; 90:878-883.
117. United Network for Organ Sharing Website. (Information downloaded from
the internet at www.unos.org).
118. Ware JE, Kosinski M, Keller SD. SF-36 Physical and mental health summary
scales: a user’s manual. Boston: The Health Institute, New England Medical
Center; 1994.
119. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF36): I. Conceptual framework and item selection. Med Care 1992; 30:473-483.
120. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor
CG, et al. Natriuretic peptide system in human heart failure. Circulation 1993;
88:1004-1009.
121. Weiner P, Waizman J, Magadle R, Berar-Yanay N, Pelled B. The effect of
specific inspiratory muscle training on the sensation of dyspnea and exercise
tolerance in patients with congestive heart failure. Clin Cardiol 1999; 22:727732.

166

122. Wohlschlaeger J, Schmitz KJ, Schmid C, Schmid KW, Keul P, Takeda A, Weis
S, Levkau B, Baba HA. Reverse remodeling following insertion of left
ventricular assist devices (LVAD): a review of the morphological and
molecular changes. Cardiovasc Res 2005; 68:376-386.
123. Wyrich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN, Wolinsky FD.
Clinically important differences in health status for patients with heart disease:
an expert consensus panel report. Am Heart J 2004; 147:615-622.
124. Yu DS, Lee DT, Woo J. Effects of relaxation therapy on psychologic distress
and symptom status in older Chinese patients with heart failure. J Psychosom
Res 2007; 62:427-437.
125. Zafeiridis A, Jeevanandam V, Houser SR, Marguiles KB. Regression of cellular
hypertrophy after left ventricular assist device support. Circulation 1998;
98:656-662.
126. Zhao XL, Gutierrez LM, Chang CF, Hosey MM, The alpha 1-subunit of
skeletal muscle L-type Ca channels is he key target for regulation by A-kinase
and protein phosphatase-1C. Biochem Biophys Res Commun 1994; 198:166173.

167

